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Sowmya Jairam 
TRANSCRIPTION REGULATION OF THE CLASS IV ALCOHOL 
DEHYDROGENASE 7 (ADH7) 
 
The class IV alcohol dehydrogenase (ADH7, µ-ADH, σ-ADH) efficiently metabolizes 
ethanol and retinol. ADH7 is expressed mainly in the upper gastrointestinal tract with no 
expression in the liver unlike the other ADHs, and is implicated in various diseases 
including alcoholism, cancer and fetal alcohol syndrome. Genome wide studies have 
identified significant associations between ADH7 variants and alcoholism and cancer, but 
the causative variants have not been identified. Due to its association with two important 
metabolic pathways and various diseases, this dissertation is focused on studying ADH7 
regulation and the effects of variants on this regulation using cell systems that replicate 
endogenous ADH7 expression. We identified elements regulating ADH7 transcription and 
observed differences in the effects of variants on gene expression. A7P-G and A7P-A, 
two promoter haplotypes differing in a single nucleotide at rs2851028, had different 
transcriptional activities and interacted with variants further upstream. A sequence 
located 12.5 kb upstream (7P10) can function as an enhancer. These complex interactions 
indicate that the effects of variants in the ADH7 regulatory elements depend on both 
sequence and cellular context, and should be considered in interpretation of the 
association of variants with alcoholism and cancer. 
 
The mechanisms governing the tissue-specific expression of ADH7 remain unexplained 
however. We identified an intergenic region (iA1C), located between ADH7 and ADH1C, 
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having enhancer blocking activity in liver-derived HepG2 cells. This enhancer blocking 
function was cell- and position- dependent with no activity seen in CP-A esophageal 
cells. iA1C had a similar effect on the ectopic SV40 enhancer. The CCCTC-binding 
factor (CTCF) bound iA1C in HepG2 cells but not in CP-A cells. Our results suggest that 
in liver-derived cells, iA1C blocks the effects of downstream ADH enhancers and thereby 
contributes to the cell specificity of ADH7 expression. Thus, while genetic factors 
determine level of ADH7 transcriptional activity, iA1C helps determine the cell 
specificity of transcription. 
 
Howard J. Edenberg, Ph.D., Chair 
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I. INTRODUCTION 
 
1. Alcohol dehydrogenases 
The medium chain dehydrogenases/reductases (MDR) constitute a large superfamily of 
close to 1000 enzymes that are involved in the oxidation of various alcohols, 
detoxification of alcohols/aldehydes and metabolism of bile acids (Persson et al., 1994). 
The alcohol dehydrogenases (ADHs) are the best studied among the MDR superfamily. 
Alcohol dehydrogenases (ADHs) are zinc-containing metalloenzymes that catalyze the 
reversible oxidation of various primary and secondary alcohols to their aldehydes (Hurley 
and Edenberg, 2012, Edenberg, 2012, Ehrig et al., 1990, Bosron and Li, 1986a). They are 
cytosolic enzymes that form homo- and heterodimers, each subunit approximately 40 
kDa. Ethanol, one of their most important substrates, is first converted to acetaldehyde 
and further oxidized by aldehyde dehydrogenases (ALDHs) to acetate. They require 
NAD+ as a coenzyme to function (Brändén and Eklund, 2008, Plapp, 2010). ADHs are 
divided into 8 different classes in vertebrates based on sequence and kinetic properties. 
Humans express classes I to V. Class VI is present in rat and deer mouse (Höög and 
Brandt, 1995); class VII and VIII in the chicken (Kedishvili et al., 1997) and zebrafish 
(Reimers et al., 2004) respectively. There is less than 70% sequence identity between the 
different classes. Dimerization occurs between members of the same class.  
 
Humans encode seven alcohol dehydrogenases, ADH1A, ADH1B, ADH1C, ADH4, 
ADH5, ADH6 and ADH7, divided into five classes (Höög and Östberg, 2011). The three 
class I enzymes ADH1A (α), ADH1B (β) and ADH1C (γ) share more than 90% identity. 
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An endogenous ADH6 enzyme encoded by Class V ADH has not been reported. ADH4 
or π (class II), ADH5 or χ (class III) and class IV enzyme (ADH7, µ-ADH, σ-ADH) are 
the other human ADHs. Class III ADH, ADH5, is the ancestral form and the only ADH 
found in invertebrates (Danielsson and Jörnvall, 1992, Julian-Sanchez et al., 2006).  
Class Gene Protein Substrates Expression 
I ADH1A α, 
ADH1A 
Ethanol, retinol Fetal and adult liver1,2, 
adult kidney3, adrenal 
gland5 
I ADH1B β, 
ADH1B 
Ethanol, retinol Fetal and adult liver1,2, 
adult kidney1,4, adrenal 
gland5, lung1,4, skin6, 
blood vessels7 
I ADH1C γ, 
ADH1C 
Ethanol, retinol Adult liver2, kidney1, 
adrenal gland5 
II ADH4 π. ADH4 Ethanol, retinol Fetal and adult liver1,5, 
lower GI tract5, spleen8 
III ADH5 χ, AH5 HMGSH, GSNO Ubiquitous4,5 
IV ADH7 µ, σ, 
ADH7 
Retinol, ethanol Stomach9,10,  
Upper GI tract 11,12 
V ADH6 - Ethanol mRNA seen in liver5 
 
Table 1: Tissue specific expression and substrate specificity of human ADHs. 
HMGSH stands for S-(hydroxymethyl) glutathione and GSNO for S-nitrosoglutathione.  
1(Smith et al., 1971), 2(Smith et al., 1972), 3(Smith, 1986), 4(Duley et al., 1985), 
5(Estonius et al., 1996), 6(Cheung et al., 1999), 7(Allali-Hassani et al., 1997), 8(Edenberg, 
2000), 9(Yin et al., 1990), 10(Kedishvili et al., 1995), 11(Yin et al., 1993), 12(Westerlund et 
al., 2007) 
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2. Expression of the ADHs 
The genes encoding the human enzymes are present in a cluster spanning approximately 
365 kb on chromosome 4q23, all in the same genomic orientation (Figure 1) (Edenberg, 
2007b). The primary site of expression for all ADHs except ADH7 is the liver (Table 1) 
 where they account for most of the elimination of ingested ethanol and metabolism of 
other alcohols. They are also expressed in other tissues at lower levels in a tissue-specific 
manner (Agarwal and Seitz, 2001, Hurley et al., 2003, Edenberg, 2000). The class I 
ADHs are expressed in lungs (Duley et al., 1985, Smith et al., 1971), kidneys (Smith, 
1986, Duley et al., 1985, Smith et al., 1971), adrenal glands (Estonius et al., 1996) and 
skin (Cheung et al., 1999) among other tissues. ADH1B is also expressed in blood vessels 
(Allali-Hassani et al., 1997). The class I ADHs exhibit temporal expression patterns with 
ADH1A and ADH1B expressed in early and late fetal liver (Estonius et al., 1996, Smith et 
al., 1972, Smith et al., 1971) respectively and ADH1C expressed postnatal (Smith et al., 
1972). ADH4, the class II isozyme is expressed in both fetal and adult liver (Smith et al., 
1971, Estonius et al., 1996), and at lower levels in the lower GI tract and spleen 
(Edenberg, 2000). ADH6 transcripts are found in adult and fetal liver and in the stomach, 
however a functional protein hasn’t been reported.  
 
 
Figure 1: The human ADH gene cluster. The gene cluster of approximately 365 kb is 
drawn to scale. The cluster is located on the long arm of chromosome 4 (4q23). Their 
genomic orientation is shown, ADH5 closest to the centromere. The genes are transcribed 
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in the direction shown. The three class I ADHs are depicted as plain arrows with the 
other genes as gray arrows. 
 
Interestingly, the two ADHs at either end of the cluster (Figure 1) have expression 
patterns most different from the other ADHs. While ADH5 is a housekeeping gene 
expressed ubiquitously in all tissues including brain, class IV ADH7 is unique as the only 
ADH not expressed in the liver. Instead, it is mainly expressed in the upper 
gastrointestinal tract down to the stomach (Yin et al., 1990, Kedishvili et al., 1995, Yin et 
al., 1997, Moreno and Parés, 1991) and in cornea and other epithelial tissues (Edenberg, 
2000, Agarwal and Seitz, 2001).  
 
Studies in rodents show Adh (Footnote 1) tissue specific expression pattern similar to 
their human counterparts (Galter et al., 2003). Rodents have 5 Adh classes similar to 
humans, but class I has only one isoform, Adh1. Interestingly, the expression of Adh1 and 
class IV Adh7 genes seemed to follow a complementary pattern with only one or the 
other expressed in any given space (Vaglenova et al., 2003, Westerlund et al., 2007). In 
the stomach where both are expressed, Adh1 is expressed in the gastric mucosa and Adh7 
in the gastric pits. In general, Adh1 is prevalent in the inner cell layers whereas Adh7 is 
expressed in the outer layers (Vaglenova et al., 2003, Westerlund et al., 2007) that have 
high cell turnover and require retinoic acid for epithelial maintenance. Adh3 is the 
ancestral ubiquitous class III alcohol dehydrogenase. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  The rodent alcohol dehydrogenases are represented as Adh for the protein and Adh for 
the gene. The rodent class II Adh4, class III Adh5 and class IV Adh7 were earlier 
referred to as Adh2, Adh3 and Adh4 respectively.	  
	   5 
3. ADH substrates 
The alcohol dehydrogenases metabolize a wide range of primary and secondary 
alcohols/aldehydes (Holmes, 1994, Boleda et al., 1993) including formaldehyde, 3β-




All ADHs can metabolize ethanol but with different affinities and catalytic efficiencies 
(Table 2). The class I enzymes have the lowest Km for ethanol, and account for greater 
than 70% of ethanol metabolism in the liver (Hurley et al., 2003). ADH4 contributes 
towards most of the remaining 30% alcohol metabolism in the liver with a Km of 34 mM 
(Hurley et al., 2003, Li et al., 1977). ADH7 has a lower affinity (higher Km) and highest 
capacity (larger Vmax) for oxidizing ethanol (Kedishvili et al., 1995). Although ethanol 
is mostly metabolized in the liver by the hepatic class I enzymes, gastric ADH7 can limit 
the amount of ethanol entering the bloodstream (Han et al., 1998, Vaglenova et al., 2003). 
This first-pass metabolism of alcohol by ADH7 can be significant if large amounts of 
alcohol are consumed in short time, as in episodes of binge drinking. ADH5 is a 
glutathione dependent enzyme with an important role in elimination of formaldehyde but 
little role in ethanol metabolism (Kaiser et al., 1993, Li et al., 1977).  




 Affinity Turnover Affinity Efficiency 
I 
ADH1A high Low moderate Low 
ADH1B highest Moderate moderate Low 
ADH1C high Low low Low 
II ADH4 low Low high Low 
III ADH5 negligible Low negligible  
IV ADH7 low Highest high High 
 
Table 2: Affinity and efficiency for ethanol (Edenberg, 2007a, Hurley and Edenberg, 
2012) and retinol (Han et al., 1998, Yang et al., 1994, Parés et al., 2008) metabolism 
by the ADHs. Km represents the binding affinity for the substrate and indicates the 
substrate concentration at which the enzyme works at 50% capacity. Vmax or kcat is the 
turnover number and is defined as the number of substrate molecules converted per 
minute at saturating substrate concentrations. The class I enzymes with the lowest Km 
values are the most efficient at low ethanol concentrations, whereas ADH7 has lower 
binding affinity and high efficiency at saturating ethanol concentrations.  
 
I. Alcohol related diseases 
Alcoholism is a polygenic, multi-factorial disease influenced by the additive effects of 
genes at several loci, and also influenced by social and environmental factors. Alcohol 
related deaths are the third preventable cause of preventable deaths in the United States 
(Mokdad et al., 2004, Danaei et al., 2009). The Diagnostic and Statistical Manual of 
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Mental Disorders (DSM), published by the American Psychiatric Association, define the 
criteria for diagnosis of alcoholism. In 2007, lifetime alcohol dependence prevalence was 
estimated to be 12.5% of the US population whereas 3.8% were currently alcohol 
dependent (Hasin et al., 2007). This study was based on DSM-4 criteria, which defined 
alcohol abuse as harmful or unhealthy drinking habits despite recurrent social, legal, 
interpersonal and work-related problems. A result of continual alcohol abuse leading to 
physical or mental addiction, alcohol dependence or alcoholism was defined as a 
maladaptive pattern of drinking with three or more of the following symptoms occurring 
in a one year period: alcohol tolerance, withdrawal, drinking more than intended and 
unsuccessful attempts to control, excessive time spent in alcohol related activities, 
impaired social or work related activities and continued used despite physical or 
psychological consequences.  
 
According to the current DSM (DSM-5) (American Psychiatry Association, 2013), a 
diagnosis of alcohol use disorder (AUD) requires at least 2 of the following criteria: 
tolerance, withdrawal, impaired control over alcohol use, unsuccessful efforts to control 
drinking, alcohol use interfering with important social, occupational or recreational 
activities and excessive time spent in alcohol related activities, continued consumption 
despite knowledge of the problem, alcohol craving, recurrent drinking in hazardous 
situations or resulting in failure of fulfilling obligations. DSM-5 removed the distinction 
between alcohol abuse and dependence and instead uses alcohol use disorder where the 
severity of the AUD is dependent on the number of criteria (Dawson et al., 2013). The 
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threshold for diagnosis of moderate AUD requires 2-3 criteria and severe AUD requires 
4+ criteria.  
 
Alcohol consumption can disrupt normal bodily functions including those of the brain, 
liver, heart, pancreas and the immune system. It is associated with several diseases 
including liver cirrhosis, steatosis, cardiovascular disease and increases risk for cancer 
(Cargiulo, 2007, Parry et al., 2011). Alcohol can also increase risk of other health 
problems like nerve damage, insomnia, erectile dysfunction, dementia and depression.  
Consumption of alcohol by a woman during any stage of pregnancy can lead to 
developmental defects in the fetus, which are collectively called Fetal Alcohol Spectrum 
Disorders (FASD) (Sokol et al., 2003, Zelner and Koren, 2013). FASD includes Fetal 
Alcohol Syndrome, partial Fetal Alcohol Syndrome, Alcohol-related 
Neurodevelopmental Disorder, and Alcohol-related birth defects. Along with the direct 
effects of alcohol, indirect effects resulting from a poor general health status can also 
cause or exacerbate existing problems. For example, deficiency of the essential nutrient 
thiamine or vitamin B1 is common in up to 80% of alcoholics, which can lead to serious 
brain disorders like the Wernicke-Korsakoff  syndrome (Martin et al., 2003).  Wernicke-
Korsakoff syndrome is a severe, debilitating condition whose symptoms include mental 
confusion, muscle coordination problems and difficulty with learning and memory. In 
addition, alcohol misuse has undesirable socio-economic consequences including 
poverty, professional instability, domestic violence, traffic accidents and fractured family 
units. 
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II. Genetics of alcoholism 
Studies have shown that genetics play an important role in the risk for alcoholism 
(McGue, 1999, Mayfield et al., 2008, Kendler et al., 1997, Goodwin et al., 1974, 
Goodwin et al., 1973, Grant, 1998, Munn-Chernoff et al., 2013, Sørensen et al., 2011). 
Compared to offspring of parents with no alcohol use disorder (AUD, defined 
previously), offspring with one AUD parent have a 2.5-fold increased risk for developing 
AUD, with the risk increasing to 4.4-fold for those with 2 AUD parents (Yoon et al., 
2013). Children adopted away from alcoholic parents have the same risk for AUD as 
their siblings raised by the biological parents (Goodwin et al., 1974, Goodwin et al., 
1973). These studies imply an important role for genetics in the development of AUD.  
 
Allelic variations in several genes have been reported to be associated with the risk for 
alcoholism (Treutlein and Rietschel, 2011, Marcella and Jens, 2012, Edenberg and 
Foroud, 2013, Rietschel and Treutlein, 2013). Apart from the ADHs and ALDHs, these 
include the gamma-aminobutyric acid A receptor, alpha 2 (GABRA2) (Edenberg et al., 
2004, Lappalainen et al., 2005, Covault et al., 2004, Fehr et al., 2006) and the adjacent 
GABRG1 (Mary-Anne et al., 2008, Jonathan et al., 2007, Ittiwut et al., 2012), cholinergic 
receptor, muscarinic 2 (CHRM2) (Luo et al., 2005, Dick et al., 2007, Wang et al., 2004), 
cholinergic receptor, nicotinic, alpha 5 (CHRNA5) (Wang et al., 2008), CHRNB3 and 
CHRNA3 (Haller et al., 2013), opioid receptor, kappa 1 (OPRK1) (Xuei et al., 2007, 
Edenberg et al., 2008a), nuclear factor of kappa light polypeptide gene enhancer in B-
cells 1 (NFκB1) (Edenberg et al., 2008b), solute carrier family 6 (neurotransmitter 
reporter), membrane 4 (SLC6A4) (Jian et al., 2013), peroxisomal trans‑2-enoyl-coA 
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reductase (PECR) (Treutlein et al., 2009), autism susceptibility candidate 2 (AUTS2) 
(Schumann et al., 2011), importin 11-5-hydroxytryptamine (serotonin) receptor 1A 
region (IPO11-HTR1A) (Zuo et al., 2013b) and ankyrin repeat and kinase domain 
containing 1 (ANKK1) (Kendler et al., 2011). 
 
III. Role of the Alcohol dehydrogenases 
The rate of ethanol metabolism determines the concentration of ethanol and its metabolite 
acetaldehyde in the different tissues, which in turn influences the effects of ethanol 
consumption on liver and the other organs. There exist variants of ADH isoforms that 
alter enzyme activities and influence a person’s ability to metabolize ethanol and 
consequently, the risk for developing alcoholism (Thomasson et al., 1993b, Goate and 
Edenberg, 1998, Osier et al., 1999, Hoog et al., 1986, Mizoi et al., 1983, Bosron and Li, 
1986a, Rietschel and Treutlein, 2013, Edenberg and Foroud, 2013, Hurley and Edenberg, 
2012). Apart from coding variants causing functional differences in enzyme activity, 
noncoding variants can alter the level of gene expression, resulting in differential enzyme 
levels that can also influence the rate of alcohol metabolism (Guindalini et al., 2005, 
Edenberg et al., 1999, Birley et al., 2008, Birley et al., 2009, Han et al., 2005) and 
thereby the susceptibility of individuals to alcoholism and other diseases (Edenberg, 
2007b).  
  
Functional variants of ADH1B and ADH1C have been studied extensively. The three 
most commonly studied ADH1B isoforms (Bosron et al., 1985, Bosron and Li, 1987, 
Hurley and Edenberg, 2012) differ in two coding SNPs, rs1229984 and rs2066702 at 
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amino acid positions 48 and 370 respectively, with the reference ADH1B*1 encoding the 
β1 isoform of the enzyme with Arginine (Arg) residues at both positions. ADH1B*2 
encodes the β2 isoform which has histidine (His) at position 48 (ADH1B-Arg48His) 
(Jörnvall et al., 1984) and the ADH1B*3 encoded β3 isoform has the amino acid cysteine 
(Cys) instead of arginine at position 370 (ADH1B-Arg370Cys) (Burnell et al., 1987). The 
β2 and β3 isoforms of ADH1B have much faster ethanol turnover (80-90 fold higher 
Vmax) than the reference β1 isoform (Hurley and Edenberg, 2012, Edenberg et al., 2006).  
 
The ADH1B*2 allele is very common in East Asian populations with an allele frequency 
of 73%, and is also present in European and American populations but at a much lower 
frequency (The 1000 genomes project, 2012). In East Asian populations where ADH1B*2 
is the major allele, several reports strongly indicate it protects against alcohol dependence 
in an additive manner (Chen et al., 1999, Whitfield, 1997, Whitfield, 2002, Thomasson et 
al., 1993b, Edenberg, 2011, Li et al., 2011, Thomasson et al., 1993a). The protective 
effect of ADH1B*2 was seen in other populations as well (Li et al., 2011, Bierut et al., 
2012, Carr et al., 2002). In both European American and African American populations, 
ADH1B*2 is associated with reduced risk for AUD, and also with a lower maximum 
number of drinks consumed in a 24 hour period (Bierut et al., 2012). It reduces binge 
drinking (Luczak et al., 2002) and the risk for alcoholism in Jews (Hasin et al., 2002), 
and is associated with unpleasant reactions following alcohol consumption (Carr et al., 
2002). It is proposed that the rapid ethanol turnover causes at least a transient elevation in 
acetaldehyde levels in one or more tissues (Israel et al., 2011, Bosron and Li, 1986b). 
Since acetaldehyde causes unpleasant reactions that include nausea and facial flushing, it 
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can lead to an aversion to further alcohol consumption. The ADH1B*3 allele is seen only 
in individuals of African descent, and was reported to protect against alcohol dependence 
(Gizer et al., 2011, Edenberg, 2007b, Edenberg et al., 2006) and the teratogenic effects of 
alcohol (Scott and Tayor, 2007), with the protective effect of the maternal allele 
continuing in the children (Dodge et al., 2014).   
 
The two most well studied ADH1C coding single nucleotide polymorphisms (SNPs) 
result in amino acid changes in two positions, 272 and 350 (Hoog et al., 1986). The γ1 
isoform encoded by ADH1C*1 has Arg and isoleucine (Ile) at positions 272 and 350 
respectively, whereas the γ2 enzyme encoded by ADH1C*2 has glutamine (Gln) and 
valine (Val) residues. The differences between the kinetic properties of the two ADH1C 
isoforms are small compared to those between the ADH1B enzymes (Hurley and 
Edenberg, 2012, Edenberg, 2007a). Though ADH1C has several reports showing 
association with alcohol dependence (Montane-Jaime et al., 2006, Zintzaras et al., 2006, 
Chen et al., 1996, Konishi et al., 2003, Konishi et al., 2004, Mulligan et al., 2003, 
Thomasson et al., 1993b, Day et al., 1991, Thomasson et al., 1993a), the significant and 
independent association of ADH1C variants with alcoholism have been inconclusive 
because of the strong Linkage Disequilibrium (LD) with the ADH1B alleles (Osier et al., 
1999, Wall, 2005, Chen et al., 1999, Choi et al., 2005). However, a recent meta-analysis 
showed that ADH1C-Ile350Val is associated with alcohol dependence and abuse with the 
strongest effects seen in Asian populations (Li et al., 2012).  
 
	   13 
ADH noncoding variants have also been associated with alcohol dependence. A study of 
110 SNPs across the ADH cluster showed that variations in ADH1A, ADH1B and ADH4 
were associated with alcoholism in European American families, with the associations 
strongest for SNPs located between the intron closest to the CDS and a region 
approximately 20 kb downstream of ADH4 (Edenberg et al., 2006). A SNP in the ADH4 
promoter was found to be associated with alcohol dependence in a Brazilian population 
(Guindalini et al., 2005) and with lower blood alcohol levels in individuals carrying the 
ALDH2*487Glu/Glu isoform (Kimura et al., 2009). This ADH4 promoter SNP, which is 
located at position -136 relative to the translational start site, was reported to have a two-
fold difference in activity between the two alleles in vitro (Edenberg et al., 1999). 
Variants in ADH1C are associated with risk in Native Americans (Mulligan et al., 2003)  
 
IV. ADHs, alcohol and cancer 
Chronic alcohol consumption is associated with an increased risk for various kinds of 
cancer (Seitz et al., 2012, Seitz et al., 2001, Haas et al., 2012, Friedenson, 2012). A meta-
analysis found that alcohol most strongly influenced risk for upper aerodigestive tract 
cancers, with significant increase also seen for cancers of the stomach, colon, rectum, 
liver, breast and ovaries (Bagnardi et al., 2001). A threshold level of consumption at 
which alcohol did not pose an increased risk for cancer was not identified. The product of 
ethanol metabolism, acetaldehyde, probably plays a major role in alcohol related 
carcinogenesis (Figure 2). Acetaldehyde is a toxic mutagen and carcinogen and can 
modify DNA by forming DNA adducts (Salaspuro, 2009). Genetic linkage studies have 
reported that individuals with polymorphisms in the ADH genes that generate 
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acetaldehyde or the ALDHs that further oxidize it show an increased risk for cancer 
(Yokoyama and Omori, 2003, Druesne-Pecollo et al., 2009, Visapää et al., 2004, 
Yokoyama et al., 1998). ADH1C*1 is associated with increased risk for cancer in heavy 
drinkers (Seitz and Meier, 2007) whereas ADH1B*1 is associated with increased risk for 
esophageal cancer even in the never/rare and moderate drinkers with the risk increasing 
with increasing alcohol consumption (Yang et al., 2010). ADH1B*2 protects against 
cancers of the upper aerodigestive tract (McKay et al., 2011, Hashibe et al., 2008), 
possibly indirectly by limiting drinking. It has also been proposed that, in contrast to the 
damaging effects of prolonged exposure to acetaldehyde, limited exposure can activate 
DNA repair mechanisms providing protection against deleterious mutations and thus, 
cancer (Israel et al., 2011).  
 
Several other mechanisms for alcohol related carcinogenesis have been postulated 
(Purohit et al., 2005, Boffetta and Hashibe, 2006, Pöschl and Seitz, 2004). Alcohol can 
act as a solvent for carcinogenic compounds and can have a local toxic effect resulting in 
cell injury and hyper proliferation, the first step to malignant transformation. Induction of 
the cytochrome CYP-450 2E1, associated with the generation of reactive oxygen species 
(ROS) and activation of procarcinogens to carcinogens, can also affect cancer risk. Other 
potential mechanisms include changes in global DNA methylation, increase in estrogen 
concentration, particularly in the context of breast cancer and nutritional deficiencies, and 
folate metabolism, among others. Finally, one of the most significant is the impairment of 
the retinoid metabolism/retinoic acid biosynthesis pathway (Yokoyama et al., 2012, Han 
et al., 1998, Duester, 1991, Zachman and Grummer, 1998) by ADHs. Retinoic acid is an 
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important signaling molecule (Rhinn and Dollé, 2012) and anti-carcinogen (Uzzaman et 
al., 2011, Garattini et al., 2007, Bushue and Wan, 2010) that is required for cell 
differentiation and maintenance of epithelial tissues. 
 
B. Retinol 
Retinol, which is oxidized reversibly to retinaldehyde (RALD) on the pathway to retinoic 
acid (RA), is another important ADH substrate. Retinoic acid is an important signaling 
molecule (Rhinn and Dollé, 2012) and anti-carcinogen (Siddikuzzaman et al., 2011) 
(Figure 2). The ADHs are part of the cytosolic medium-chain dehydrogenase (MDR) 
superfamily, and along with the short-chain dehydrogenases (SDR), constitute the 
enzymes involved in retinol metabolism: the retinol dehydrogenases (Persson et al., 
2008). As in ethanol metabolism, the various enzymes have different activities for retinol 
metabolism (Table 2), with the NAD+ dependent enzymes (including ADHs) proposed to 
be best suited for retinol oxidation and NADP+ dependent enzymes for retinaldehyde 
reduction based on kinetic constants (Parés et al., 2008).  
 
Among the ADHs, the class I enzymes have similar Km values for retinol metabolism, 
between 30 to 76 µM (Kedishvili et al., 1995, Parés et al., 2008, Han et al., 1998, Yang et 
al., 1994). Adh1-/- null mice are phenotypically similar to wild type mice when 
maintained on a vitamin A sufficient diet (Molotkov et al., 2002b, Molotkov et al., 
2002a). On a vitamin A deficient diet, both the Adh1 double null mutants and wild type 
mice show similar growth deficiencies that could be rescued on vitamin A 
supplementation. However, the Adh1-/- mice show decreased metabolism of excess retinol 
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leading to RA toxicity (Molotkov et al., 2002b, Molotkov et al., 2002a) compared to wild 
type mice. ADH4, with low Km and low kcat values, is more active for retinol 
metabolism (Kedishvili et al., 1995, Parés et al., 2008, Han et al., 1998, Yang et al., 
1994). Both the class I and class II enzymes are important in elimination of hepatic 
retinol excess.  
 
ADH5 has little activity with retinoids but Adh5-/- mutant mice showed postnatal lethality 
and growth deficiency, correlating with decreased retinoic acid generation, which could 
be rescued with supplement vitamin A (Molotkov et al., 2002b). The low but ubiquitous 
RA generation by ADH5 may be important in tissues that lack the more active enzymes 
and only require low levels of RA. ADH5 also has a role in elimination of excess retinol.  
 
ADH7 has the highest activity for both retinol oxidation and retinaldehyde reduction and 
the highest efficiency for retinol metabolism with low Km and high kcat values (Table 2) 
(Kedishvili et al., 1995, Parés et al., 2008, Han et al., 1998, Yang et al., 1994, Gallego et 
al., 2006) among all retinol dehydrogenases. Adh5-/- mice and Adh7-/- (null) mice are 
phenotypically similar to wild type mice on vitamin A sufficient diet but exhibit severe 
postnatal lethality and growth deficiencies on a vitamin A deficient diet (Deltour et al., 
1999, Molotkov et al., 2002b, Molotkov et al., 2002a). Thus, ADH7 is important in 
RALD generation and RA biosynthesis in the tissues where it is expressed but not in the 
elimination of excess retinol, indicating the ADHs have non-overlapping functions in 
retinol metabolism. The ubiquitous ADH5 is involved in low-level RA generation in all 
tissues. The class I and class IV ADHs exhibit much greater activity towards retinol and 
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are necessary for RA generation and signaling, mediated through the retinoid receptors, 
in tissues where they are expressed, particularly on a vitamin A deficient diet.  
 
4. Retinoid receptors 
The biological responses to retinoids, which include both natural ligands (retinol/vitamin 
A metabolites) and synthetic analogs, are mediated by intracellular retinoic acid receptors 
(RARs) and retinoid X receptors (RXR) (Bushue and Wan, 2010, Germain et al., 2006, 
Connolly et al., 2013, Chambon, 1996, Aranda and Pascual, 2001). Retinoid receptors 
belong to the larger superfamily of steroid/thyroid hormone nuclear receptors that share a 
common modular structure consisting of a variable amino-terminal domain (A/B), a 
highly conserved central DNA binding domain (C or DBD), a hinge region (D) and a 
well conserved carboxy terminal ligand binding domain (E or LBD). The DBD contains 
two highly conserved zinc fingers important for DNA binding specificity, whereas the 
LBD has a common structure formed by 12 α-helices that undergo a conformational 
change on ligand binding creating binding surfaces for transcription coregulators.  
 
The receptors are present in both the nucleus and the cytoplasm, with heterodimerization 
with RXRs and ligand binding shifting the subcellular localization to the nucleus (Kumar 
et al., 2006, Kawata, 2001, Kesler and Paschal, 2009). Nuclear localization is mediated 
by nuclear localization signals, typically located in the DBD-hinge region (C/D domain) 
of the receptors, by interacting with nuclear import receptors at the cytoplasmic side. The 
receptor-importin complex is transported through the nuclear pore complex to the 
nucleus, and the receptor released from the complex in a RAN-GTP dependent manner. 
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The nuclear receptors are typically exported to the cytoplasm by export receptors that 
interact with nuclear export signals within the nuclear receptors and function in a manner 
opposite to the import receptors, or by piggybacking on binding protein partners such as 
transcription coregulators. Nuclear receptors can undergo multiple rounds of 
nucleocytoplasmic shuttling in their lifecycle. While nuclear localization is essential for 
the classical or genomic pathway of regulating gene transcription by binding target gene 
promoters, cytoplasmic localization may be important for efficient receptor turnover and 
for nongenomic functions such as interactions with various signaling pathways occurring 
in the cytoplasm (Kesler and Paschal, 2009, Germain et al., 2006, Connolly et al., 2013). 
 
The RAR subfamily binds two naturally occurring ligands, all-trans-retinoic-acid and 9-
cis-retinoic-acid, whereas RXRs bind 9-cis-retinoic-acids alone. Each subfamily has 
multiple isotypes (α, β and γ), which in turn have multiple isoforms due to alternative 
splicing and differential usage of two promoters (Chambon, 1996, Germain et al., 2006, 
Robinson-Rechavi et al., 2003, Aranda and Pascual, 2001). There are two major isoforms 
of RARα (α1 and α2) and RARγ (γ1 and γ2), and four major isoforms of RARβ (β1-β4). 
The different isoforms of each retinoid receptor subfamily have highly conserved DNA- 
and ligand binding domains, but differ in their NH2-terminal regions (A/B domain). The 
retinoid receptors contain two transcription activation functions that can act 
synergistically: a constitutive ligand-independent function AF-1 in the A/B region that is 
specific to each isoform and a ligand-dependent AF-2 function in the LBD that is 
common to all isoforms of a specific receptor isotype. The AF-2 function contains an 
activation domain core motif that is highly conserved in all transcriptionally active 
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nuclear hormone receptors and is essential for ligand-dependent interactions of the 
receptor, but not for ligand or DNA binding.  
 
The retinoid receptors bind as RAR/RXR heterodimers to retinoic acid response elements 
(RAREs) to mediate the appropriate cellular response to ligand binding (Chambon, 1996, 
Germain et al., 2006, Aranda and Pascual, 2001). RAREs are direct repeats of the core 
recognition motif PuGG/TTCA separated by a 5 bp (DR5) or 2 bp (DR2) or 1 bp (DR1) 
spacer. The RAR/RXR heterodimer is nonpermissive and does not lead to activation on 
binding by an RXR ligand alone. However, binding of the RAR ligand allows activation 
with the subsequent binding of the RXR ligand resulting in synergism and increase in the 
transcriptional response to the RAR ligand. In the absence of retinoic acid, RAR/RXR 
heterodimers repress transcription by interacting with the corepressors NCoR, SMRT, 
Sin3A and Sin3B and recruiting histone deacetylases (HDACs) or DNA 
methyltransferases (DNMTs) that leads to a condensed chromatin structure. Retinoic acid 
binding causes a conformational change in the RARs leading to the release of 
corepressors and recruitment of transcriptional coactivators and subsequent activation of 
gene transcription. Ligand bound nuclear receptors are found in a complex with multiple 
proteins of diverse functions, including the coactivators with histone acetyltransferase 
(HAT) activity, ATP-driven chromatin remodeling activity and finally proteins that 
interact with and recruit the basal transcription machinery. This is the classical 
mechanism of regulation by retinoic acid receptors which leads to cell differentiation, cell 
arrest and apoptosis.  
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RARs/RXRs can also heterodimerize with other receptors, including the estrogen 
receptor (ER), peroxisome proliferator-activated receptor (PPAR) and vitamin D receptor 
(VDR). In this nonclassical or nongenomic pathway where they form unconventional 
heterodimers, RARs and RXRs regulate their partner’s signaling pathways, often having 
functions opposite to the classical pathway (Balmer and Blomhoff, 2002, Connolly et al., 
2013, Aranda and Pascual, 2001). These contrary effects include inhibition of apoptosis 
and upregulation of pro-survival genes in cancer cells in response to RA binding instead 
of promoting differentiation, which may allow cancer cells to develop resistance to RA 
treatment. The AF-1 transactivation and ligand binding domains of RARs are 
phosphorylated by multiple kinases in response to various signals, which can lead to 
ligand independent activation of target genes. RARs also interfere with AP-1, NF-κB, 
and VEGF mediated regulation and chromatin remodeling activities thus integrating 
diverse signaling pathways.  
 
Disruption in retinoid signaling pathways are linked to cancer. Retinoids have been 
successfully used as therapeutic agents for cancer treatment, primarily because of their 
ability to arrest proliferation and induce differentiation (Connolly et al., 2013, Bushue 
and Wan, 2010, Evans and Kaye, 1999, Germain et al., 2006). Exogenous expression of 
the tumor suppressor RARβ, which is epigenetically silenced in many tumors, causes 
RA-dependent and RA-independent apoptosis and growth arrest. The best-studied 
example of RA as a cancer therapeutic tool is acute promyelocytic leukemia (APL). APL 
is caused by chromosomal translocation between RARα and promyelocyte leukemia 
(PML) genes resulting in aberrant signaling of both proteins. The fusion PML- RARα 
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fusion protein binds the corepressors NCoR and SMRT more efficiently than wild type 
RARα and causes repression of RARα target genes, which in turn prevents 
differentiation of APL cells. Treatment with supraphysiological doses of all trans retinoic 
acid (ATRA) leads to remission in APL patients; patients that develop resistance to 
ATRA and relapse can be effectively treated with other RARα specific agonists for 
complete remission.  
 
However, retinoids have not been as successful in the treatment of solid tumors despite 
their success with hematological malignancies (Connolly et al., 2013, Bushue and Wan, 
2010, Evans and Kaye, 1999, Germain et al., 2006). A possible mechanism of resistance 
to RA therapy is the epigenetic silencing of RARβ early in carcinogenesis, which can 
potentially be overcome by combining RA therapy with DNMT and HDAC inhibitors. 
Other possible mechanisms include the presence of cancer stem cells that resist 
differentiation, loss of RARβ expression by mechanisms other than epigenetic silencing 
and crosstalk between retinoid and other signaling pathways allowing cancer cells to 
bypass specific targeted therapies. Additionally, the therapeutic potential of retinoids is 
limited by the associated toxic side affects caused by their pleiotropic functions. The side 
effects of varying severity include teratogenicity, headache, bone toxicity and 
mucocutaneous cytotoxicity. Thus, further studies are focused on both overcoming the 
resistance to retinoids and decreasing the adverse side effects to them.  
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Figure 2: ADH substrates and their biological significance. Ethanol and retinol 
compete for the ADH catalytic site. Ethanol can competitively inhibit retinol metabolism 
with the inhibitory constants of each ADH (Ki) similar to the corresponding affinity 
constant (Km). Ethanol metabolite acetaldehyde is a toxic mutagen and carcinogen while 
retinoic acid has important roles in signaling and directing cellular growth and 
differentiation with anti-carcinogen properties.  
! ! ! !!!!!Folate!metabolism!!!Modification!of! ! !DNA!structure/!sequence/! ! ! ! !!methylation!status! ! ! ! Secondary!hyperproliferation! !!!!!!!! ADH! ! ! ! ALDH!Ethanol!!! ! !!!!!Acetaldehyde!! ! !!!!!!!!!Acetic!acid!!! !!! ! ! !!!! ! ADH! ! ! ! !!!!!!!ALDH!Retinol!!! ! !!!!!!Retinalaldehyde!! ! !!!!!!!!!! !!!Retinoic!acid!!!! !! Retinoic!acid!!! receptors!!!! !!!!!!!!!!Signaling/Gene!regulation!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! Epithelial!maintenance/! ! ! AntiBcarcinogenic!! Cellular!growth!and!differentiation!!
Competitive!inhibition!
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Since ethanol and retinol bind the same active site, ethanol competitively inhibits retinol 
metabolism (Yin et al., 2003, Duester, 1991) (Figure 2) by class I, class II and class IV 
ADHs with inhibition constants ranging from 0.037 to 11 mM (Han et al., 1998).  Retinol 
metabolism by the ADH linked pathway can be significantly disrupted by physiologically 
attainable concentrations of ethanol from social/heavy drinking. This inhibition of the 
retinoic acid biosynthesis pathway is implicated in fetal alcohol syndrome (Zachman and 
Grummer, 1998, Duester, 1991) and cancer (Purohit et al., 2005, Boffetta and Hashibe, 
2006). 
 
5. ADH7 and disease associations 
Genome wide association studies (GWAS) have identified associations of ADH7 with 
alcoholism, drug dependence and cancer (Table 5). Association studies are useful in 
identifying variants contributing to diseases like alcoholism, which is multifactorial and 
influenced by several different genes (Murray and Gurling, 1982). Alleles identified by 
GWAS are typically not the causal variants, but are in linkage disequilibrium (LD) with 
them, particularly where the association with disease is not apparent (Marian, 2012, 
Clark, 2003). LD is when alleles at two or more loci associate in a non-random fashion 
(are inherited together more often than would be expected based on their individual 
frequencies) (Reich et al., 2001). LOD, D’ and r2 are three measures for LD with a D’ or r2 
score of 1 indicating the alleles have not been separated by recombination. The 
identification of the significant association of any SNP with a disease phenotype from a 
GWAS study represents the finding that might represent any of the SNPs that are in a 
high degree of LD with the originally identified SNP.   
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Figure 3: Linkage disequilibrium in the ADH region. LD among single-nucleotide 
polymorphisms (SNPs) in the alcohol dehydrogenase (ADH) genes represented by the D' 
values in CEU population (International HapMap Consortium, 2010, The International 
HapMap, 2005) (Hapmap Data Rel 27 Phase II+III, Feb09, on NCBI B36 assembly, 
dbSNP b126). D' is a measure of LD between two genetic markers with a value of D'= 1 
meaning no recombination has occurred and the markers are in complete LD. The 
intensity of the shading is proportional to the extent of LD between the markers with 
darker shades representing greater LD and lighter shades representing lower LD. SNPs 
within genes generally are in high LD with each other, whereas SNPs in different genes 
typically have a lower LD between them. Positions of the ADHs are indicated on the top. 
Most of the ADH genes except ADH7 are in moderately strong LD (indicated by the 
mostly clear areas in the vicinity of ADH7).  
 
 





Figure 4: LD plot of the ADH7 gene. LD is represented by D' values in CEU population 
(International HapMap Consortium, 2010, The International HapMap, 2005) (Hapmap 
Data Rel 27 Phase II+III, Feb09, on NCBI B36 assembly, dbSNP b126). The intensity of 
the box color is proportional to the strength of LD between two genetic markers. The 
ADH7 gene and upstream and downstream regions are depicted in the picture at the top; 
+1 represents the ADH7 translational start site. ADH7 is divided into two LD blocks with 
a recombination hotspot within the gene; each block is in moderately strong LD within 
itself but not with the other block.  	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LD analysis in the ADH region reveals an interesting pattern. There is little LD between 
ADH7 and the rest of the ADH cluster, with a break in the intergenic region between 
ADH7 and ADH1C (Figure 3).  ADH7 itself is divided into two haplotype blocks with a 
recombination hotspot within intron 7 of the gene (Figure 4) (Han et al., 2005, Birley et 
al., 2008, Edenberg et al., 2006). SNPs located in the 5’ haplotype block are associated 
with both blood alcohol and breath alcohol concentrations, and account for approximately 
18% of a major quantitative trait locus within the ADH region influencing alcohol 
metabolism, or 11% of the total genetic variance (Birley et al., 2009, Birley et al., 2008). 
The C allele of rs1154458, located in intron 6 of ADH7, is associated with protection 
against alcoholism (Osier et al., 2004, Han et al., 2005). Among individuals carrying the 
incontrovertibly protective ADH1B*2 polymorphism, the allele frequency of rs1154458-
C (0.135) was reported to be significantly lower in alcoholics compared to rs1154458-G 
(0.345), whereas the allele frequencies in nonalcoholic controls were similar (0.331 for 
rs1154458-C vs 0.324 for rs1154458-G). This indicates that the protection cannot be 
attributed to ADH1B*2 alone (Osier et al., 2004). The absence of significant linkage 
disequilibirum between rs1154458 or any other known ADH7 SNP and the ADH1B*2 
allele indicates that the genetic association of ADH7 with alcoholism is an independent 
association (Han et al., 2005).  
 
Two ADH7 non-synonymous coding variants are known. rs1573496 causes an Alanine 
(Ala) to Glycine (Gly) substitution at position 92, whereas rs59534319 (which is rare to 
uncommon in most populations) causes Lysine (Lys) to Glutamic acid (Glu) substitution 
at position 238. The GG and CG genotypes at rs1573496 confer a protective effect 
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against cancers of the upper aero-digestive tract (McKay et al., 2011, Hashibe et al., 
2008, Wei et al., 2010), where ADH7 is expressed. There is no reported association of 
rs59534319 with disease, although it is only 30-bp away from the synonymous SNP 
rs971074, which is associated with a higher risk for drug dependence (Levran et al., 
2009, Luo et al., 2007). Since neither of the non-synonymous coding variants rs1573496 
explain all ADH7 associations, it is likely that many of these associations reflect 
differences in regulation of expression, as has been found for other complex diseases 
(Ward and Kellis, 2012, Pennisi, 2011, Gregory and Jay, 2011). It is therefore important 
to study ADH7 transcription regulation. 	  
6. Elements regulating gene transcription 
 
A) Promoters 
Transcriptional regulation involves complex interaction of different kinds of cis-acting 
regulatory elements, proteins that bind these elements, and chromatin structure (Maston, 
2006). The gene promoter may be the most important regulatory sequence because all the 
events preceding transcriptional activation ultimately lead to the basal transcription 
machinery at the gene promoter. The ubiquitous and highly conserved RNA polymerase 
II (RNAPII) core promoter drives transcription in all eukaryotic cells, and is the 
minimum sequence required to initiate gene transcription containing the transcription 
start site. (Juven-Gershon et al., 2008, Juven-Gershon and Kadonaga, 2010). Core 
promoter recognition is the first step in the mechanism of transcription initiation (Thomas 
and Chiang, 2006). In combination with non-prototypical binding partners, the core 
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promoter can also influence regulation of cell specific transcription (Goodrich and Tjian, 
2010). While the core promoter typically has binding sites for general transcription 
factors, the proximal promoter immediately upstream of the transcription start site 
contains primary regulatory elements and specific transcription binding sites. The region 
upstream to the gene promoter typically contains transcriptional regulatory elements 
marked by characteristics such as conservation across species, DNaseI hypersensitivity, 
histone modifications and binding sites for transcription factors (Maston, 2006). 
Upstream regulatory elements can affect gene expression by affecting promoter activity.  
 
B) Enhancers and silencers 
Enhancers, silencers and Locus Control Regions (LCRs) can control gene expression in 
an orientation-independent and position-independent manner, and from locations as 
remote as 100 kb from the gene (Bondarenko et al., 2003, Dean, 2006, Ong and Corces, 
2011, Jin et al., 2011). Enhancers bind activator proteins that activate transcription either 
by directly recruiting general transcription factors and RNA polymerase II and/or by 
recruiting chromatin remodeling complexes that make the chromatin accessible to general 
transcription factors and RNA polymerase II (Szutorisz et al., 2005, Arnosti and 
Kulkarni, 2005, Chin-Tong and Victor, 2011). Though enhancers can activate promoters 
over long distance, they generally activate the nearest promoter preferentially. On the 
other hand, silencers repress transcription either by interfering with general transcription 
factors assembly or by binding repressors that in turn inhibit assembly of general 
transcription factors (Ogbourne and Antalis, 1998). LCRs enhance the expression of 
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Insulators or Boundary elements restrict the effects of long-range chromatin interactions. 
The eukaryotic genome is organized into domains comprised of individual genes or 
clusters of genes with distinct patterns of expression (Lunyak, 2008, Kadauke and Blobel, 
2009). Active and inactive chromatin domains are often in close proximity to one 
another, and enhancer and silencer elements operate over large distances to regulate the 
genes in these domains. Boundary elements or insulators composed of specific sequences 
function to prevent regulatory elements present within a domain from promiscuously 
activating or suppressing the expression of genes located within adjacent domains 
(Bushey et al., 2008, Barkess and West, 2012, Moltó et al., 2009).  
 
Chromatin insulators have emerged as important factors in the spatial and topological 
organization of higher order chromatin structures and functional transcriptional domains 
(Phillips-Cremins and Corces, 2013, Van Bortle and Corces, 2012). Insulators typically 
exhibit either one or both of two characteristics 1) “enhancer blocking” function, i.e., 
when placed between the enhancer and promoter they block enhancers from activating 
the promoter and 2) “barrier” function of protecting transgenes from position effects. 
Insulators can interact with each other, with other regulatory elements and with the 
nuclear architecture forming loops that encourage specific enhancer-promoter 
interactions while restricting others (Murrell, 2011, Valenzuela and Kamakaka, 2006, 
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Wallace and Felsenfeld, 2007) depending on various factors including cell type and target 
enhancers and promoters. All vertebrate insulators identified so far bind CTCF, a zinc 
finger protein that can recognize diverse DNA elements (Phillips and Corces, 2009, 
Holwerda and De Laat, 2013).  
 
D) CTCF 
CTCF is a highly conserved ubiquitous zinc finger protein and can function as both a 
transcriptional activator (Vostrov and Quitschke, 1997) and repressor (Filippova et al., 
1996), and is involved in insulation, genomic imprinting and X-chromosome inactivation 
(Filippova, 2008). CTCF is known to interact with various transcription factors, 
chromatin modifying enzymes and other regulatory proteins, with the end result of 
activation, repression or insulation dependent on the combination of factors present at the 
site in a particular cell or tissue (Merkenschlager and Odom, 2013, Lee and Iyer, 2012, 
Barkess and West, 2012). CTCF can also form homodimers, and can interact with the 
nuclear lamina causing DNA looping and formation of cis- and trans- chromatin domains 
and influencing cross talk between gene promoters and regulatory elements (Ren et al., 
2012, Phillips and Corces, 2009, Williams and Flavell, 2008). Cell specific interactions 
between CTCF bound sequences are known to regulate the cell specific expression of 
linked genes such as the beta-globin cluster (Junier et al., 2012, Ren et al., 2012). CTCF 
binding is dependent on the DNA sequence methylation status since methylation of the 
CpG nucleotides within the CTCF binding site can disrupt binding (Wang et al., 2012). 
CTCF binding and function can also be influenced by the neighboring DNA binding 
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factors (Weth and Renkawitz, 2011). CTCF binding is, therefore, a marker for potential 
regulatory function.  
 
7. Transcription regulation of the ADHs 
Proximal promoter elements are important in regulating local gene expression and those 
pertaining to ADHs have been studied extensively to understand the regulation of ADH 
expression (Edenberg, 2000). The proximal promoters of different ADH classes are 
packed with binding sites for multiple proteins, particularly liver specific transcription 
factors considering that the liver is the primary site of expression for 6 of the seven 
human ADHs. All ADHs except ADH5 contain a TATA box, whereas ADH5 contains a 
GC-rich sequence instead. The CCAAT/enhancer-binding protein (C/EBP) and activator 
protein-1 (AP-1) family of transcription factors, specificity protein 1 (Sp1), nuclear 
factor-1 (NF-1), upstream stimulatory factor (USF), hepatocyte nuclear factor 1 (HNF1), 
glucocorticoid receptors (GR) and retinoic acid receptors (RAR, RXR) (Edenberg, 2000) 
are implicated in ADH regulation.  
 
CCAAT/enhancer-binding proteins (C/EBP) are liver enriched transcription factors and 
play an important role in the regulation of all the ADH genes (Stewart et al., 1991, Brown 
et al., 1996, Edenberg, 2000). They are a highly conserved family of proteins that have 
basic leucine zipper domain, which is involved in the dimerization and DNA binding 
(Tsukada et al., 2011). The AP-1 family of basic-region leucine zipper (bZIP) 
transcription factors include JUN, FOS, ATF and MAF sub-family proteins that can 
homo- and hetero-dimerize. AP-1 proteins contribute both to basal gene expression, as 
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well as in response to various stimuli including serum, growth factors and oncoproteins, 
and a variety of environmental stresses, such as UV radiation (Karin et al., 1997). They 
can activate or repress transcription, and have both oncogenic and anti-oncogenic 
properties (Robert and Erwin, 2003) depending on the context. The HNF1 (or 
Transcription factor 1 (TCF1)) transcription factor is essential for the activation of 
several liver specific genes though it is also expressed in the epithelial cells of endoderm 
derived organs (Tronche and Yaniv, 1992). HNF1-α binds as a homo- or heterodimer 
with its paralog HNF1-β, a transcription factor with the same DNA sequence specificity 
(Mendel et al., 1991). Mutations in HNF1-α and HNF1-β are causal factors for maturity-
onset diabetes of the young (MODY) types 3 and 5 respectively (Raile et al., 2008, 
Gardner and Tai, 2012).  
 
Known cis-regulatory elements in the ADH proximal promoter regions, however, do not 
fully explain the tissue-specific expression of the ADHs. The human class I ADH genes 
share 80-90% similarity up to 300 bp upstream of the transcription start site, but show 
different spatio-temporal expression (Edenberg, 2000). Regions extending to 110 kb 
upstream and 104 kb downstream could induce ADH class I expression in liver at levels 
comparable to endogenous levels in mice (Szalai et al., 2002); 12 kb upstream and 23 kb 
downstream regions were not sufficient to activate the class I ADH promoter. This 
suggests that distal elements are involved in ADH regulation.  A HNF1-bound enhancer 
located in the intergenic region between ADH1C and ADH7 was found to be both 
necessary and sufficient to induce expression of all 3 human ADH class I genes in liver 
(Su et al., 2006). Distal elements have also been identified upstream of ADH1A, one of 
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them regulating tissue-specificity (Dannenberg et al., 2005). A potent FOXA-dependent 
enhancer, which is liver specific and is located upstream of ADH4, increased ADH4 and 
ADH1B promoter activities 50-fold in hepatoma cells (Pochareddy and Edenberg, 2010). 
However, distant regulatory mechanisms of the other classes of ADH genes have not been 
addressed yet, especially those that regulate the differential pattern of ADH7 and ADH 
class I tissue specific expression.  
 
8. ADH7 transcription regulation 
A 232 bp proximal promoter of ADH7 is functional in HeLa, CV-1 (monkey kidney) and 
H4IIE-C3 (rat liver) cell lines (Kotagiri and Edenberg, 1998). Four transcription factor 
binding sites were identified within the proximal promoter. Site A contains a consensus 
AP-1 binding site and was bound by transcription factors including c-Jun, a component of 
AP-1, in the three cell lines tested. Mutation of the AP-1 transcription factor binding site 
preventing c-Jun binding decreased promoter activity to 8-12% of the wild type 
promoter, indicating a critical role for AP-1 in ADH7 gene regulation (Kotagiri and 
Edenberg, 1998). Multiple binding sites for C/EBP transcription factors were identified. 
Site-directed mutagenesis of site B that could be bound by C/EBP reduced promoter 
activity by 75% indicating the importance of this site in ADH7 regulation. Site C could be 
bound by both c-Jun and C/EBPα, and the mutated sequence doubled activity in CV-1 
cells while having no significant effect in H4IIE-C3 cells making it the only cell-specific 
regulatory element in this proximal promoter. The DNA footprint for the fourth site D 
was observed only in CV-1 cells, suggesting it may be cell specific. Sites A, C and D are 
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conserved in the orthologous mouse gene Adh3 indicating they may be functional in the 
mouse (Kotagiri and Edenberg, 1998).  
 
Co-transfection of the ADH7 promoter with C/EBP-α or C/EBP-β expression plasmids 
led to decreases in promoter activity in CV-1 cells that do not express their endogenous 
C/EBP-α (Kotagiri and Edenberg, 1998). Since these C/EBP transcription factors 
especially C/EBP-α are prominently expressed in the liver, the negative effect of C/EBP 
co-expression suggests one mechanism that contributes to ADH7 not being expressed 
there. However, these elements do not fully explain the tissue specific transcriptional 
regulation of ADH7. 
 
Other transcription factors, including the retinoic acid receptor family, STAT family and 
HNF family proteins, are predicted by PROMO (Messeguer et al., 2002) to bind in the 
ADH7 proximal region. The Transfac Matrix database (Matys et al., 2003) predicted 
binding sites for the transcription factors FOXO3 and FOXJ2 in the 1.5 kb region 
immediately upstream of ADH7, but ENCODE (Rosenbloom et al., 2013) data do not 
show binding of any transcription factors in that region in the cell lines tested. In a 
genome-wide study of alcohol dependence in Han Chinese, ADH7 was reported to be 
hypomethylated in alcoholics, although the sites were not shown (Zuo et al., 2013a). The 
UCSC Genome Browser shows two sites of methylation in the proximal promoter region 
(at bp -148 and -787) and one site further upstream (at -12059); these are partially 
methylated in many cell types, including HepG2. None are at polymorphic sites, and their 
effect on gene expression is not known. Binding of NFκB, Maf (v-maf avian 
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Musculoaponeurotic fibrosarcoma oncogene homolog) and IRF (interferon regulatory 
factor) proteins have been shown to bind sequences further upstream in some cell lines.  
 
9. Research Objectives 
The overarching objective of this dissertation is the study of ADH7 transcription 
regulation. ADH7 is involved in several important metabolic pathways and is unique 
among the ADHs in its expression, affinity and efficiency for its substrates and in having 
little to no LD with the rest of the cluster. Genome wide association studies (GWAS) 
have shown that ADH7 is independently and significantly associated with several 
diseases including widely prevalent alcoholism and cancer, but its regulation is not fully 
explained. This dissertation is a study on the proximal and more distal elements involved 
in cell-specific ADH7 regulation, and how genetic variants affect function. Studies were 
done in cell systems with contrasting ADH7 expression, using bioinformatics and 
experimental approaches. 
 
The first main research objective is the identification of elements regulating ADH7 
transcription and the effect of variants on this regulation. Since all except one of the 
reported disease associations are noncoding and remain unexplained, at least some are 
likely from regulatory element variants affecting transcriptional activity that are in LD 
with the GWAS identified genetic markers. An understanding of the ADH7 regulatory 
regions and the effects of variants can help interpret the association data and point toward 
likely causal variants (Gregory and Jay, 2011). Since most of the disease associations 
belong to the ADH7 5’ LD block and regulatory elements typically reside upstream of the 
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coding region and are conserved across species, the 12.5 kb conserved region upstream of 
ADH7 was the focus of this study. 
 
The second objective was to gain an understanding of the tissue-specific expression of 
ADH7, specifically the lack of expression in the liver despite the proximity of the class I 
ADH enhancer located in the intergenic region between ADH1C and ADH7 and other 
liver functional ADH enhancers. In silico prediction tools were first used to identify 
potential chromatin insulators based on the hypothesis that such elements can block liver 
enhancers from wrongly activating ADH7 in the liver. Then experimental studies were 
done to study the functional role of the test element in relevant cell systems. This study 
investigated one mechanism by which ADH7 expression in the liver is regulated. 
 
10. Cell systems 
The cell systems used in this dissertation replicate ADH7 tissue specific expression and 
therefore make great in vitro models for studying cell specific expression. CP-A 
esophageal cells express ADH7 endogenously while HepG2 hepatoma cells do not 
express ADH7, similar to the pattern seen in the respective tissues. MEF mouse 
embryonic fibroblasts also express Adh7. 
 
A. HepG2 cells 
HepG2 human hepatoma cells (ATCC, Manassas, VA; HB-8065) are adherent cells with 
an epithelial morphology. The cells grow in monolayers forming small aggregates. The 
cell line was derived from a fifteen year old Caucasian male with a well-differentiated 
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hepatocellular carcinoma (Knowles et al., 1980). It is non-tumorigenic in 
immunosuppressed mice. Because of the absence of viral infection, HepG2 cells are a 
popular model for studying hepatocellular carcinoma and other liver diseases (Xia et al., 
2013, Costantini et al., 2013). They express both intact and inducible phase I (including 
several ADHs (Table 3)) and phase II enzymes required for activation and detoxification 
of xenobiotics, and therefore are a good in vitro model for studying drug metabolism 
(Mersch-Sundermann et al., 2004, Diamond et al., 1980).  
 
B. CP-A cells 
CP-A cells (ATCC, CRL-4027) (Palanca-Wessels et al., 2003, Palanca-Wessels et al., 
1998) are an hTERT immortalized cell line obtained from a non-dysplastic Barrett’s 
Esophagus tissue of an adult male. They have an epithelial like morphology and grow as 
adherent cells in monolayers. CP-A cells represent a great model to study esophageal 
cancers particularly Barrett’s esophagus(Kosoff et al., 2012) and ADH7 regulation 
because it is the only human cell line identified so far that expresses ADH7 
endogenously. 
 
C. MEF cells 
MEF (mouse embryonic fibroblast) cells (Xu, 2001) immortalized by infection with a 
recombinant retrovirus expressing SV40 large T antigen are frequently used as feeder 
cells to support the growth of embryonic stem (ES) cells and to maintain them in an 
undifferentiated state (Villa-Diaz et al., 2013). They express Adh7 endogenously and can 
be used as a second point for comparison on ADH7 regulation.   
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II. MATERIALS AND METHODS 
1. Bioinformatics 
The mammalian conservation track in the UCSC genome browser was used to identify 
the regions of conservation between human and other vertebrates in the sequence 
upstream of ADH7. Published literature and online databases including ALFRED (Allele 
frequency database) (Rajeevan et al., 2012) and HGMD (Human gene mutation database) 
(Stenson et al., 2009) were used to identify disease associated SNPs. Linkage 
Disequilibrium (LD) data from the NCBI Hapmap database (Hapmap Data Rel 27, Feb 
09) (International HapMap Consortium, 2010) and the 1000 genome database (The 1000 
genomes project, 2012) (based on Ensembl v69, Oct 2012) were used to identify LD 
between SNPs in the vicinity of ADH7 and disease-associated SNPs. The Hapmap and 
dbSNP databases were used to identify naturally occurring haplotypes and the samples to 
use as templates for obtaining them. The insulatordb database (Bao et al., 2008) was used 
to identify potential CTCF binding sites in the ADH region, particularly in the vicinity of 
ADH7. 
 
2. Cloning of test fragments and their variants 
Two naturally occurring haplotypes of an 841-bp ADH7 proximal promoter (A7P-G/A; -
19 to -859-bp relative to ADH7 translation start site) were generated by PCR 
amplification from an anonymous human DNA sample using Invitrogen Platinum Pfx 
polymerase (Life Technologies, Grand Island, NY; catalog 11708-013). The two 
promoter haplotypes, A7P-A and A7P-G were cloned into HindIII and BglII sites in the 
multiple cloning site of the pXP2 luciferase vector (SK, 1988), oriented so that the 
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promoters drive luciferase expression. Restriction sites for NcoI, Acc65I, NotI and XhoI 
were included in the forward primer of A7P to facilitate further subcloning. Fragments of 
approximately 1 kb each extending up to -12.5 kb upstream of the ADH7 gene were 
amplified from human DNA using Invitrogen Platinum Pfx polymerase. DNA samples 
used as templates in PCR amplification of naturally occurring haplotypes of 7P5, 7P6, 
7P8 and 7P10 (Table 4) were obtained from the Coriell Institute for Medical Research 
(Camden, New Jersey, USA). Fragments 7P2 to 7P10 (except 7P6) were cloned into 
Acc65I and XhoI sites of pXP2 upstream of promoters A7P-G and A7P-A, and tested for 
effect on each promoter activity. 7P6 was cloned into NcoI and XhoI sites of pXP2 
upstream of A7P-G and A7P-A because Acc65I cut within the 7P6 sequence. 7P10 sub-
fragments were cloned into HindIII and XhoI sites upstream of A7P-A. 7P10 sub-
fragment E2 was cloned into HindIII and XhoI sites upstream of A7P-A in the reverse 
orientation to make E2flip, and into ApaI and SwaI sites to make E2far. E2 was cloned 
into HindIII and XhoI sites upstream of luciferase gene to make E2prom. All primers are 
listed in Appendix A (Table 8). 
 
The A7P-A promoter haplotype cloned into pXP2 was used as the parent construct for 
insulator assays. The approximately 240 bp fragment corresponding to class I specific 
HNF1 bound enhancer (ENH) (Su et al., 2006) was cloned into PciI and NdeI sites 
approximately 1 kb upstream of the A7P promoter fragment in pXP2. ENH forward 
primer contained restriction sites for MluI, BssHII, NruI and the reverse primer had 
AsiSI, AfeI, NgoMIV restriction sites to facilitate further sub-cloning. The known 
insulator element, XL9 (Majumder et al., 2008) and the 965 bp test fragment located 2 kb 
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upstream of HNF1 bound enhancer identified as a potential CTCF binding site in silico 
were cloned into the AsiSI and NgoMIV sites, and/or the MluI and NruI sites for the 
enhancer blocking assays. DNA samples used as templates in PCR amplification of the 
three naturally occurring haplotypes of iA1C were obtained from the Coriell Institute for 
Medical Research (Camden, New Jersey, USA). All primers are listed in Appendix B 
(Table 9). 
 
For tests with non-homologous elements, the 965 bp iA1C fragment was cloned into the 
pGL3 control vector (Groskreutz et al., 1995) containing the luciferase reporter gene 
driven by the SV40 promoter, with the SV40 enhancer more than 2 kb upstream of the 
SV40 promoter. The test and control elements were placed between the promoter and 
enhancer between the MluI and BglII sites in the multiple cloning site (MCS) 
immediately upstream of the SV40 promoter. 
 
3. Site directed mutagenesis 
The QuikChange Lightning Multi Site-Directed Mutagenesis kit (Agilent Technologies, 
Santa Clara, CA; 210516) and unlabeled oligos (iA1C-Osh) used for EMSA assays were 
used to make full length shuffled iA1C plasmid (with only the specific 5-6 nt different 
from the WT sequence). 1.5 µl of 100 ng/µl DNA template and 1.5 µl of 5 µM mutagenic 
primer were added to relevant amounts of dNTP mix, 10X QuikChange Lightning multi 
reaction buffer, QuikChange Lightning Multi enzyme blend and double-distilled water to 
make up 25 µl reaction volume as per manufacturer’s instructions. The PCR reaction was 
set up as follows: 95C – 2 min; <95C – 20 s, 55C – 30 s, 65C – 4.5 min> 30 cycles; 65C 
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– 5 min; 4C. 1 µl of DpnI restriction enzyme was added directly to the PCR product and 
vortexed gently to mix, then incubating the reaction for 5 min at 37C to digest parental 
strand. 1.5 µl of DpnI treated mutated PCR product was transformed into XL10-Gold 
ultracompetent cells according to manufacturer’s instructions.  
 
4. Cell culture and Transient transfections 
HepG2 human hepatoma cells (ATCC, Manassas, VA; HB-8065) were cultured in MEM 
(ATCC) with 10% fetal bovine serum (Invitrogen, Carlsbad, CA), 4 mM glutamine 
(Thermo Scientific Hyclone, Waltham, MA) and 1X Penicillin and Streptomycin 
(Thermo Scientific Hyclone) on cell bind surface plates (Corning Inc., Tewksbury, MA; 
CLS3296) at 37°C. Transient transfections in HepG2 cells were done by seeding 0.8 x 
105 cells per well in Corning cell bind surface 12-well plates (Corning Inc., Tewksbury, 
MA; CLS3336). 24 h after seeding, medium was changed and cells were transfected with 
1.52 pmoles of test DNA, 15 ng of pCMV β-galactosidase plasmid (Clontech, Mountain 
View, CA) and enough pUC19 DNA to get a total DNA amount of 1 µg per well. 2 µl per 
well Fugene HD (Roche, Indianapolis, IN) was used as the transfection reagent. 
 
CP-A cells (ATCC, CRL-4027) are an hTERT immortalized cell line obtained from a 
non-dysplastic Barrett’s Esophagus tissue. CP-A cells were cultured in Keratinocyte-
SFM (Invitrogen, Carlsbad, CA; 17005-042, with each 500 ml supplemented with 25 mg 
Bovine pituitary extract and 2.5 µg human recombinant epidermal growth factor supplied 
with the medium) plus 10% FBS and 1% Penicillin-Streptomycin (ATCC, 30-2300) at 37 
°C.  For transient transfections, CP-A cells were seeded at 3.75 X 105 cells per well in 
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12-well cell bind plates (Corning Inc., Tewksbury, MA; CLS3336). Transfections were 
done 24 h after seeding as described previously. 
 
MEF (mouse embryonic fibroblast) cells immortalized by infection with a recombinant 
retrovirus expressing SV40 large T antigen were cultured in DMEM supplemented with 
10% fetal bovine serum (Invitrogen, Carlsbad, CA), and 1X Penicillin and Streptomycin 
(Thermo Scientific Hyclone, Waltham, MA) at 37°C. MEF cells were seeded at 0.8 X 105 
cells per well in 12-well cell bind plates (Corning Inc., Tewksbury, MA; CLS3336) for 
reporter gene assays. Transfections were done 24 h after seeding as described previously. 
 
5. Reporter gene assays 
HepG2 cells were collected in ice cold 1X PBS made from 10 X PBS solution (Fisher 
Bioreagents, Hampton, New Hampshire; BP3994) 30 h after transfection. Cells were 
collected by centrifugation and the resulting pellet was resuspended in 100 µl of 1X 
Reporter Lysis buffer (Promega, Madison, WI; E3971). Cell lysates were prepared by 
repeated freeze-thaw cycles in dry ice and water. Lysates were centrifuged to pellet cell 
debris and the supernatants transferred to new tubes. Luciferase activity was measured on 
a Spectramax LS (Molecular Devices, Sunnyvale, CA) using the Luciferase assay system 
(Promega, Madison, WI; E1501), with 20 µl of the extract. β-galactosidase assays were 
carried out with 5 µl extract using the Galacto-Light System (Tropix, Bedford, MA). 
 
CP-A cells were harvested 24 h after transfections by washing once with 1X PBS, and 
scraping into 250 µl 1X Reporter lysis buffer. Lysates were then freeze-thawed 
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repeatedly and centrifuged to pellet down cell debris, as described earlier. 20 µl and 10 µl 
of CP-A cell supernatant was used for luciferase and β-galactosidase assays respectively. 
MEF cells were collected 24 h after transfection in 250 µl 1X Reporter lysis buffer, and 
assayed for luciferase and β-galactosidase activity as earlier.  
 
All test fragments were transfected in at least 3 independent experiments, with each 
experiment having at least 3 replicates. Relative activity of a test construct was calculated 
by normalizing each luciferase activity to the internal control β-galactosidase activity, to 
correct for the transfection efficiency, and then calculating the ratio of normalized 
luciferase activity of test fragment to that of the promoter haplotype driving the luciferase 
expression in the construct. P-values were calculated using two-tailed t-tests of the 
normalized values. 
 
6. Nuclear and cytoplasmic extraction 
Nuclear extracts were prepared from HepG2 cells using NE-PER Nuclear and 
Cytoplasmic Extraction Reagents (Thermoscientific Pierce, Waltham, MA; 78835), 
following the manufacturer's protocol. Protein concentrations were measured by Bio-Rad 
protein assay (Bio-Rad, Hercules, CA; 500-0002). 
 
7. Electrophoretic Mobility Shift Assay (EMSA) 
EMSAs were carried out with 40 bp double-strand oligonucleotides with 10 bp on either 
side of the 20 bp predicted CTCF binding site. Oligonucleotides were synthesized 
(Integrated DNA Technologies) with a 5′ 6-FAM label on one of the strands and then 
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annealed to complementary unlabeled oligonucleotides in 10 mM Tris (pH 8.0), 1 mM 
EDTA (pH 8.0) and 100 mM sodium chloride. Protein binding reactions were carried out 
with 0.25 µM of the annealed oligonucleotides and 6 or 8 µg of the nuclear extracts in 
10 mM HEPES (pH 7.9), 60 mM potassium chloride, 5 mM magnesium chloride, 1 mM 
EDTA, 1 mM DTT, 7% glycerol, 1 µg of poly (dIdC), 1X protease inhibitor and 0.1 mM 
ZnSO4. Nuclear extracts were first incubated with premix containing all components 
except oligonucleotides for 5-10 min on ice.  
 
Labeled oligonucleotides (0.5 µM per reaction) were then incubated with the nuclear 
extract for 16 min at 25°C. In competitor assays, unlabeled competitor oligonucleotides 
in molar excess to the labeled oligonucleotides were added to the reaction and incubated 
at RT for 10 min before addition of the probe. For supershift assays, 2 µg of the antibody 
was added to each reaction. CTCF (Millipore 07-729), and CTCF (Santa Cruz., sc-
5916X) antibodies were tested. DNA–protein complexes were electrophoresed on 6% 
polyacrylamide Novex DNA Retardation Gels (Invitrogen; EC63652BOX) for 45 min in 
ice-cold 0.5X TBE running buffer (45 mM Tris-borate and 1 mM EDTA, pH 8.3) and 
then scanned with fluorescent image analyzer FLA-5100 (Fujifilm, Valhalla, NY) at 
473 nm with LPB filter. The gel was run on ice to avoid overheating. 
 
8. Chromatin immunoprecipitation (ChIP) 
ChIP assays were done in HepG2 and CP-A cells with Anti-CTCF (Millipore; 07-729), 
positive control H3 and negative control IgG antibodies supplied with the SimpleChIP 
Enzymatic Chromatin IP kit (Cell Signaling Technology, Danvers, MA; 9003). Assays 
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were done following manufacturers protocol, with sonication conditions optimized for 
the two cell types. CP-A cells were sonicated 3 times for 7 s each and HepG2 cells were 
sonicated 5 times for 15 s each, with a 60 second interval on ice between sonication 
bursts. The immunoprecipitations were done overnight at 4C with gentle rotation, 
followed by incubation with magnetic beads for 3 h at 4C. Following DNA elution, 
quantification was done by qPCR and standard PCR. Eleven primer pairs amplifying 
overlapping iA1C sub-fragments approximately 100 bp in size were tested for enrichment 
in the Anti-CTCF IP sample with yields calculated as % input. Human RPL30 primers 
(Cell Signaling Technology, Danvers, MA; 7014S) specific to exon 3 of RPL30 gene 
bound by Histone H3 served as a random non-specific control for CTCF binding; and as 
positive control for H3 binding.  
 
9. Adenovirus infection of cells 
HepG2 cells were plated in two 12 well plates with each plate having alternate columns 
seeded at 60-70% confluence (24 wells in total- 12 each for shCTCF and shControl). 24 h 
after seeding, first column in each plate was infected with adenovirus encoding CTCF 
shRNA (shCTCF) and third column infected with adenovirus encoding control shRNA 
(shctrl). Both shCTCF and shctrl adenovirus were generously provided by Dr. Paul 
Herring (Rodenberg et al., 2010, Ishihara et al., 2006). The adenovirus was prepared for 
infection by diluting in EMEM Complete medium (used for culturing HepG2 cells) by 
adding 20 µl/well of each virus to 400 µl/well of EMEM Complete medium (700 µl/well 
complete medium for 6 well plates). After removing medium from cells, they were 
washed once with ice cold 1X PBS; after which 420 µl of diluted shCTCF or shctrl was 
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added directly to the cells. Cells were returned to incubator for 4 h and an additional 1ml 
complete medium added at this point. Cells were then harvested 72 h after infection. 
Media was changed daily until harvest. 6 wells of each plate (shCTCF or shctrl 
infections) were used for RNA and protein extraction respectively. For RNA extraction, 
400 µl Trizol was added directly to cells, incubated at RT for 3 min and then pipetted up 
and down to break up DNA. The cells lysed in Trizol were stored at -80C until lysates 
were ready to be used, after which the regular protocol for Trizol extraction was 
followed. cDNA synthesis was done from both Trizol extracted RNA and column 
purified RNA. For protein extraction, cells were washed with ice cold 1X PBS and then 
lysed in 150 µl RIPA buffer +inhibitors placed on ice and let sit at RT for 10-15 min. Cell 
lysates were then scraped and collected into prechilled 1.5 ml Eppendorf tubes, spun 2 
min at 4C and supernatant transferred to fresh tubes (2 tubes---one for most of the sample 
and one for protein assay ~ 20 µl). The crude protein extracts were then frozen at -80C. 
 
10. RNA extraction and purification, Real time PCR 
HepG2 and CP-A RNA were extracted using Trizol (Life Technologies, Carlsbad) and 
purified using the Qiagen RNeasy mini kit (Qiagen, Germantown, MD; 74106) following 
manufacturer’s protocol. DNA concentrations were determined by absorbance at 260 nm 
using a Nanodrop spectrophotometer (Thermo Scientific, Waltham, MA). Superscript III 
First-strand synthesis system (Invitrogen, Carlsbad, CA; 18080-051) was used to 
synthesize cDNA from 1 µg RNA following the manufacturer’s protocol. qPCR assays 
were performed using 10 µl of 2X Power SYBR Green mastermix (Life technologies, 
Carlsbad, CA; 4367659), 2 µl of 3 mM primers, 3 µl of 2X diluted cDNA and water in 
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the StepOnePlus Real-time PCR system (Life Technologies, Carlsbad, CA; 4376598). No 
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III. CHAPTER I 2 
SINGLE NUCLEOTIDE POLYMORPHISMS INTERACT TO AFFECT ADH7 
TRANSCRIPTION 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  Large	  portions	  of	  the	  text	  in	  this	  chapter	  are	  reproduced	  from	  the	  published	  article:	  Jairam, S and Edenberg, HJ. Single Nucleotide Polymorphisms interact to affect 
ADH7 transcription JAIRAM, S. & EDENBERG, H. J. 2014. Single-Nucleotide 
Polymorphisms Interact to Affect ADH7 Transcription. Alcoholism: Clinical and 
Experimental Research, n/a-n/a.	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1. INTRODUCTION 
Genome wide studies have identified associations of ADH7 with alcoholism, drug 
dependence and cancer. SNPs located in the 5’ haplotype block are associated with both 
blood alcohol and breath alcohol concentrations (Table 5). The intronic SNP rs1154458 
is linked to protection against alcoholism. Two ADH7 non-synonymous coding variants 
are known, rs1573496 (Ala92Gly) and rs59534319 (Lys238Glu; rare to uncommon in 
most populations). Rs1573496-G confers a protective effect against cancers of the upper 
aero-digestive tract where ADH7 is expressed. There is no reported association of 
rs59534319 with disease, although it is only 30 bp away from the synonymous SNP 
rs971074, which is associated with a higher risk for drug dependence. It is likely that 
many of these associations reflect differences in regulation of expression, as has been 
found for other complex diseases (Ward and Kellis, 2012, Pennisi, 2011, Gregory and 
Jay, 2011). An understanding of the ADH7 regulatory regions and the effects of variants 
on regulation can help interpret the association data and point toward likely causal 
variants. 
 
The goal of this study is to identify elements regulating ADH7 transcription and examine 
how genetic variants affect regulation. Two human cell lines and a mouse cell line with 
contrasting ADH7 expression were chosen to study ADH7 gene regulation. CP-A 
epithelial cells, derived from a non-dysplastic Barrett’s esophageal sample immortalized 
by hTERT (Palanca-Wessels et al., 1998), and MEF (mouse embryonic fibroblast) cells 
immortalized with the SV40 T antigen express ADH7 endogenously. HepG2 human 
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hepatoma cells (Knowles et al., 1980) do not express ADH7. We identified regulatory 
elements, including some with cell-specificity, and detected interactions among them.  
 
2. RESULTS 
A. ADH7 proximal promoter variant rs2851028 and its effect on activity 
There are two haplotypes of the 822 bp fragment that extends from -1 bp to -823 bp with 
respect to the ADH7 translation start site, A7P-A and A7P-G, that differ at a single SNP: 
rs2851028, at -630 bp (Figure 5). Both haplotypes were tested for promoter activity by 
transient transfections in CP-A esophageal cells and MEF mouse embryonic fibroblasts 
that express ADH7 and in HepG2 hepatoma cells that do not (Table 3). These cells 
represent the complementary pattern of ADH7 expression seen in humans (Westerlund et 
al., 2007, Vaglenova et al., 2003).  Both haplotypes of the promoter fragment were active 
in all tested cell types (Figure 6). The promoter construct with the minor G allele was 
1.6- to 2-fold more active than the promoter with the A allele independent of cell 
type.  The empty vector pXP2 had no activity in either cell type.  
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Gene CP-A HepG2 MEF Gene 
ADH1A - - 
N/A Adh1 ADH1B - - 
ADH1C + - 
ADH4 - + - Adh4 
ADH5 + + + Adh5 
ADH6 + + N/A Adh6 
ADH7 + - + Adh7 
 
Table 3: ADH gene expression in CP-A human esophageal, HepG2 human 
hepatoma and MEF mouse embryonic fibroblast cells. Expression was tested using 
RT-PCR and the results are depicted as a “+” for gene expressed or “-” for no gene 
expression. The human ADH genes are listed on the left and mouse Adhs on the right. 
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Figure 5: Map of the ADH7 promoter and upstream fragments. Map is drawn to 
scale in chromosomal orientation with promoter (black solid), monomorphic fragments 
(below the line) and polymorphic fragments (on the line). Transcription occurs right to 
left (arrow) from the translation start site (TSS). SNPs are shown, with the three LD 
blocks represented as solid black circles, plain circles or grey circle (rs17589306). 
 
    
Figure 6: ADH7 promoter haplotypes are differently active in HepG2, CP-A and 
MEF cells. The relative activity is the ratio of promoter activity of the G construct (A7P-
G) to the A construct (A7P-A) within each cell line. Standard errors of mean are shown 
(n≥12). P-value for the difference between the A and G constructs was 3 x 10-5 (HepG2 
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B. Upstream regulatory regions 
Conservation extended approximately 12.5 kb upstream of ADH7, with only patches of 
conservation seen in the rest of the intergenic sequence between ADH7 and C4orf17, 
which flanks the ADH gene cluster on one end. We therefore focused our studies on this 
12.5 kb region. Fragments of approximately 1 kb (Figure 5) were cloned upstream of the 
A7P-G and A7P-A promoters and tested for effects on promoter activity by transient 
transfections. Opposite haplotypes of fragments having multiple known haplotypes were 
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Table 4: Upstream fragments and their variants tested. Test fragment location is with 
respect to the ADH7 TSS. DNA source: Samples from Coriell Institute (NA number) or 
anonymous DNA used to amplify test fragments of different haplotypes. Haplotypes 
tested are listed in order of the SNPs. Haplotype frequencies in three populations 
obtained from the Hapmap (The International HapMap, 2005) and 1000 genome (THE 
1000 GENOMES PROJECT, 2012) databases; CEU, Northern and Western Europeans 
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C. Monomorphic fragments  
Fragments 7P2, 7P3, and 7P4, together spanning from -762 bp to -3479 bp, did not have 
any reported SNPs, nor did fragments 7P7 and 7P9 (Figure 5). These monomorphic 
fragments showed different activity depending on which promoter haplotype they were 
combined with and which cells they were tested in. Fragment 7P2 reduced activity of 
both promoters by 10-15% in CP-A cells (Figure 7A) and reduced the activity of the 
A7P-A promoter by a similar 20% in HepG2 cells, but had a significantly larger effect on 
A7P-G activity in HepG2 cells (55% reduction) (Figure 7B). In MEF cells, 7P2 
considerably decreased both promoter activities but had a stronger effect on A7P-G 
(51%) (Figure 7C). 7P3 significantly increased both promoter activities in CP-A cells 
but had little effect on the activity of A7P-A in HepG2 cells, and significantly reduced 
activity of A7P-G (by 38%) in HepG2 cells. On the other hand, it had no effect on A7P-G 
in MEF cells, but increased A7P-A activity by 30%. 7P4 had stronger effects on the A7P-
G promoter in CP-A and HepG2 cells, but in different directions: it increased A7P-A and 
A7P-G promoter activities in CP-A cells (by 15% and 40% respectively) (Figure 7A), 
while decreasing both activities in HepG2 cells (by 20% and 35% respectively). 7P4 had 
an opposite effect on the two promoters in MEF cells: increasing A7P-A activity by 20% 
and reducing A7P-G activity by 12% (Figure 7C). In CP-A cells, 7P7 increased A7P-A 
activity but decreased A7P-G activity to a similar extent, whereas in HepG2 cells it 
decreased both promoters, with a much stronger effect on A7P-G (Figure 7B). 7P7 
showed a more pronounced effect in MEF cells by increasing A7P-A activity 100% and 
decreasing A7P-G by 25% (Figure 7C). 7P9 had little effect on A7P-A activity in CP-A 
	   56 
cells, but strongly decreased A7P-G activity. In HepG2 cells and MEF cells, 7P9 
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 7C. MEF cells 
   
Figure 7: Activity of monomorphic fragments on the two promoter haplotypes. 
Transient transfections of the monomorphic upstream sequences 7P2, 7P3, 7P4, 7P7 and 
7P9 were done in A) CP-A cells, B) HepG2 cells and C) MEF cells. Relative activity of 
each construct represents the ratio of normalized luciferase activity of the test fragment to 
the A7P-A (black) promoter or A7P-G (grey shaded), whichever the fragment was tested 
in. Scales of vertical axes are different. Error bars represent standard errors of mean. T-
tests were done for each construct and the corresponding promoter construct in each cell 
type. Significant differences between transcriptional activities (calculated as normalized 
luciferase activities) are represented by stars: * indicate p-values ≤ 0.03; ** indicate p-
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D. Polymorphic fragments 
Fragments 7P5, 7P6, 7P8 and 7P10 contain SNPs (Figure 5) in linkage disequilibrium 
with variants having significant disease associations (Table 5) (Osier et al., 2004, Han et 
al., 2005, Birley et al., 2008, Birley et al., 2009, Hashibe et al., 2008, McKay et al., 2011, 
Cadoni et al., 2012, Levran et al., 2009, Wei et al., 2010). Transient transfections were 
done with two naturally occurring haplotypes of each of these fragments (Table 4) 
cloned upstream of both A7P-A and A7P-G promoters. 7P5-ATAC had no effect on 
either promoter activity in CP-A cells (Figure 8A) while strongly reducing both promoter 
activities (about 50%) in HepG2 cells (Figure 8B). 7P5-GCGT showed both promoter-
specific and cell-specific function: it had no effect on A7P-A but decreased A7P-G 
activity by 20% in CP-A cells; in HepG2 cells, it increased A7P-A activity by 20% but 
decreased A7P-G activity by 40%. In MEF cells, 7P5-ATAC decreased both promoter 
activities whereas 7P5-GCGT showed promoter specific effects by increasing A7P-A by 
55% and decreasing A7P-G by 30% (Figure 8C). 
 
Both 7P6 haplotypes decreased both promoter activities by 36-47% in CP-A cells 
(Figure 8A). In HepG2 cells (Figure 8B), 7P6-A reduced A7P-A activity by 20% with 
no significant effect of 7P6-G. Both 7P6 haplotypes showed a dramatic 85% reduction of 
A7P-G activity. Both 7P6 variants decreased both promoter activities in MEF cells. The 
7P8 haplotypes 7P8-GC and 7P8-AG increased A7P-A activity in CP-A cells by 40% and 
20% respectively but had nearly no effect on A7P-G (Figure 8A).  In HepG2 cells 
(Figure 8B), both 7P8 variants decreased A7P-A activity by 20% and A7P-G activity by 
approximately 60%. 7P8-AG had opposite effects in MEF cells increasing A7P-A by 
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60% and decreasing A7P-G activity by a similar amount, while 7P8-GC decreased both 
promoter activities (Figure 8C). 
 
The 7P10 variants had the greatest positive impact on promoter activity. In CP-A cells, 
both 7P10 haplotypes increased the A7P-A promoter activity 2.3-2.4 fold while having 
significantly smaller effects on A7P-G activity (1.1-1.3 fold) (Figure 8A). In HepG2 
cells, 7P10-CTT increased A7P-A activity by 40% with no effect on A7P-G, and 7P10-
TTT had no effect on A7P-A but decreased A7P-G activity by 40% (Figure 8B). In MEF 
cells, similar interactions between variants were seen with 7P10 but with a more 
pronounced effect (Figure 8C). 7P10-CTT decreased both promoter activities, but the 
TTT variant had a strong promoter-specific effect. 7P10-TTT increased A7P-A activity 
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8A. CP-A cells 
  
8B. HepG2 cells 
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8C. MEF cells: 
 
Figure 8: Activity of polymorphic fragments on the two promoter haplotypes. 
Transient transfections of two naturally occurring haplotypes of each polymorphic 
fragment (7P5, 7P6, 7P8 and 7P10) were done in A) CP-A cells, B) HepG2 cells and C) 
MEF cells. Each sequence was tested for effect on both promoters A7P-G and A7P-A. 
Relative activity of each construct represents the ratio of normalized luciferase activity to 
the promoter on which it was tested, A7P-G (grey shaded) or A7P-A (black). Error bars 
represent standard errors of mean. Scales of vertical axes are different. P-values reflect 
the differences between the normalized luciferase activities of each construct and the 
corresponding promoter construct. Relative activities are shown with * indicating p-
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7P10, which had the greatest effect on activity of the A7P-A promoter, was fragmented 
into three partially overlapping sub-sequences to better localize the regulatory element(s) 
(Figure 9A). Transient transfections cells showed that one of the sub-fragments, 7P10-E2 
had the strongest effect on promoter activity in both CP-A and MEF cells (Figure 9B), 
which was more than twice that of the whole fragment. The other sub-fragments 7P10-E1 
and 7P10-E3 had some activity, but less than the whole fragment. The effect of each sub-
fragment was very similar in the two cell types tested. 
 
Given its location and relatively strong effect on promoter activity, 7P10-E2 was tested to 
determine if it functioned as an enhancer in CP-A cells (Figure 10A). It did not function 
alone as a promoter (7P10-E2prom; (Figure 10B)). It did function nearly as well in either 
orientation (E2flip vs E2), and when moved further away from the promoter, fulfilling 















Figure 9: Localization of regulatory elements in fragment 7P10. A) 7P10 sub-
fragments approximately 500 bp in size are shown as oriented on the chromosome, with 
E1 being the farthest upstream from ADH7. B) Activity of sub-fragments of 7P10 in CP-
A (black solid) and MEF cells (grey solid). P-values reflect the differences between the 
normalized luciferase activities of each construct and the promoter construct in 
corresponding cell type. * indicate p-values ≤ 7 × 10-4; ** indicate p-values ≤ 1 × 10-6; 
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10A.   
   
10B.  
  
Figure 10: Upstream fragment 7P10-E2 acts as an enhancer. A) Map of the pXP2 
vector construct with E2 or E2flip (E2 in reverse orientation) cloned into the HindIII and 
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the ApaI and SwaI sites 3.5 kb away from the promoter to test for position effects. B) 
7P10-E2 tested for promoter activity (E2prom) and enhancer properties, orientation 
independence (E2flip) and position independence (E2far), by transient transfections in 
CP-A cells. Activity was measured relative to A7P-A. Error bars represent standard error 
of means. P-values reflect the differences between the normalized luciferase activity of 
each construct and A7P-A, and are all ≤ 1 × 10-9 indicated by ***
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3. DISCUSSION 
We have identified elements regulating ADH7 promoter activity in physiologically 
relevant cell systems, and observed functional differences in the activities of naturally 
occurring haplotypes of both the promoter and upstream regulatory elements. There are 
cell-specific differences, and also differences in how the upstream sequences affect the 
promoter with the A allele at rs2851028 vs. the G allele. In both CP-A and MEF cells, 
which express ADH7 endogenously, some fragments increase activity of the promoter 
with the A allele more than they do the promoter with the G allele, and others increase 
the A-promoter while decreasing activity of the G-promoter with the general trend 
favoring the former pattern. Most of the upstream fragments reduce promoter activity in 
HepG2 cells, which do not express endogenous ADH7, with a stronger effect on the 
promoter with the G allele. In general, regulatory elements have similar effects in CP-A 
and MEF cells, being particularly apparent in the effects of 7P10 sub-fragments in the 
two cell types, indicating that regulation is dependent on the status of ADH7 expression. 
Our study of polymorphic fragments carrying opposite haplotypes of upstream sequences 
shows that variants have significant effects on regulatory function depending on cell type 
and DNA sequence.  
 
The pattern of linkage disequilibrium among the upstream variants and those associated 
with diseases shows three distinct LD blocks (Table 5). Variants in block 1, which 
contains the A7P promoter with rs2851028 and the upstream 7P5 fragment with 
rs1154473, are in strong LD (r2 ≥ 0.8, D’ ≥ 0.9) with variant rs1154458, associated with 
alcoholism (Osier et al., 2004, Han et al., 2005), rs2654849, associated with age of onset 
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of regular alcohol use (van Beek JH, 2010) and rs1154460, associated with upper aero-
digestive tract (UAT) cancers (Hakenewerth et al., 2011, Oze et al., 2009). The more 
active allele of the promoter, rs2851028-G, is in LD with the C allele of rs1154458, 
which protects against alcoholism (Osier et al., 2004, Han et al., 2005). This is analogous 
to the faster-metabolizing isoforms of ADH1B and ADH1C, which have protective effects 
on risk for alcoholism and excessive drinking (Chen et al., 1999, Thomasson et al., 1993, 
Edenberg and Foroud, 2013, Hurley and Edenberg, 2012, Bierut et al., 2012). Though the 
7P5 haplotypes have similar effects relative to each promoter in CP-A cells, there is a 
potential synergistic interaction between the two 7P5-GCGT haplotype and rs2851028-A 
in HepG2 cells. The minor G upstream allele of rs1154473 located in 7P5 and belonging 
to this LD block gains binding sites for several transcription factors including STAT4, 
NFκB, YY1 and RelA proteins. 	  	  
rs1154460, also in block 1 (Table 5), is associated with upper aerodigestive cancers, the 
risk increasing with increasing alcohol consumption (Hakenewerth et al., 2011). In this 
case, it is the less active A allele of rs2851028 that is in LD with the risk allele for cancer, 
rs1154460-A; the cancer risk increased with increasing alcohol consumption 
(Hakenewerth et al., 2011, Oze et al., 2009). The direction of affect is similar to the 
association of the less active ADH1C*2 with cancer, with the risk increasing additively 
with alcohol consumption (Peters et al., 2005, Bongaerts et al., 2011, Xue et al., 2012). 
Retinoic acid and its precursor retinol are anti-carcinogens (Siddikuzzaman et al., 2011) 
and signaling molecules (Rhinn and Dollé, 2012) that are important for the maintenance 
of epithelial tissues (Osanai et al., 2007, Everts, 2012) including those expressing ADH7.  
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Although there are other retinol dehydrogenases, ADH7 has the greatest efficiency for 
oxidation of retinol to retinaldehyde (Parés et al., 2008) and an important, non-redundant 
role to play in retinoic acid synthesis. The tissue-specific expression of ADH7, the role of 
RA as an anti-carcinogen and in maintenance of these tissues, and the role of ADH7 in 
the retinol metabolism suggest that the inhibition of this RA biosynthesis pathway can 
increase risk for cancer in the tissues that express ADH7. This is highlighted both by 
morphological changes including inflammation and intestinal metaplasia in the gastric 
mucosa when ADH7 activity is reduced (Matsumoto et al., 2005) and by the severe 
growth and survival defects when Adh7-/- mice are raised on a vitamin-A deficient diet 
(Deltour et al., 1999). By influencing ADH7 protein levels, the less active A7P-A 
promoter can slow retinol metabolism relative to the more active A7P-G promoter in the 
presence of ethanol due to the competition for the catalytic site between the two 
substrates, particularly at high ethanol concentrations. This can in turn disrupt RA 
functions including cell differentiation and growth arrest leading to increased risk for 
cancer (Figure 2). The risk for cancer increasing with increasing alcohol consumption 
supports this possibility. The promoter A7P can bind transcription factors C/EBP, CREB 
and AP-1 (Kotagiri and Edenberg, 1998) and has consensus binding sites for others 
including HNF1, Oct1, FOXP3 and GRalpha transcription factors (Myers et al., 
Messeguer et al., 2002, Farré et al., 2003). A7P-G loses the HNF1 binding sites, but gains 
IRF-2 transcription factor binding site supporting the possibility of allele-specific 
regulatory protein binding that may be responsible for difference in activity.  
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rs1154458- Protection against alcoholism 
(Han et al., 2005, Osier et al., 2004) 
rs2654849- Age at onset of regular alcohol 
use (van Beek JH, 2010) 
rs1154460- UAT cancers (Oze et al., 2009, 
Hakenewerth et al., 2011) 
  













rs1154461- Alcohol metabolism (Birley et 
al., 2009, Birley et al., 2008) 
rs1154468- Alcohol metabolism 
rs894363- Alcohol metabolism 
rs1154470- Alcohol metabolism; 
Extraversion and conscientiousness in 





    
3 rs17589306  7P10 rs971074- Drug dependence & heroin 
addiction (Luo et al., 2007, Levran et al., 
2009), 
rs1573496- UAT cancer (Hashibe et al., 
2008, McKay et al., 2011, Wei et al., 2010, 
Cadoni and Pandolfini, 2012) 
Table 5: Upstream SNPs in LD with disease associated SNPs. Upstream SNPs in LD 
with disease associated SNPs and the test fragments containing them are listed. SNPs 
with r2 ≥ 0.8, D’ ≥ 0.9 are defined as within an LD block. The disease phenotypes 
associated with each SNP are listed, along with the references. 
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Block 2 contains 6 upstream SNPs in fragments 7P5, 7P6, 7P8 and 7P10, located 
between -4667 bp to –12578 bp (Table 5). These upstream fragments affect regulatory 
function in a cell- and promoter haplotype-dependent manner. The minor alleles of these 
SNPs are in LD with the minor alleles of SNPs associated with the early stages of alcohol 
metabolism (Birley et al., 2008, Birley et al., 2009) but have no association with 
alcoholism or cancer. This suggests that different cis-sequences and possibly different 
mechanisms underlie the various disease phenotypes.  
 
The third LD block comprises the 7P10 enhancer SNP rs17589306, in LD with two SNPs 
associated with cancer (Table 5) (Hashibe et al., 2008, Wei et al., 2010, McKay et al., 
2011, Cadoni and Pandolfini, 2012) and drug dependence (Levran et al., 2009, Luo et al., 
2007) but not, thus far, with alcoholism or alcohol metabolism (Birley et al., 2008). One 
of these, rs1573496, is a coding SNP associated with upper aerodigestive cancer (Hashibe 
et al., 2008, McKay et al., 2011, Wei et al., 2010, Cadoni and Pandolfini, 2012); it is in 
complete LD with the enhancer SNP rs17589306. rs971074, a synonymous SNP, is 
associated with drug dependence (Luo et al., 2007, Levran et al., 2009). The other non-
synonymous coding polymorphism rs59534319, 30 bp away from rs971074, is 
uncommon to rare in most populations, and no associations have yet been reported; it is, 
however, possible that it contributes to the reported associations in this linkage block. 
Thus the effects of a particular regulatory polymorphism are complex, and depend upon 
the sequence context of other polymorphisms and on cell type. This can complicate 
interpretation of association data.  
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7P10-E2 is DNaseI hypersensitive in many cell lines (Sandstrom et al.). It was shown to 
bind various transcription factors (Myers et al.), including the NFkB and AP-1 
superfamily of transcription factors, in cells having no endogenous ADH7. The AP-1 
family related Maf (v-maf avian Musculoaponeurotic fibrosarcoma oncogene homolog) 
proteins, that bind 7P10-E2 in some cell lines, are frequently associated with enhancer 
elements and are expressed in the esophagus (Motohashi et al., 2004, Chen et al., 2012) 
(where ADH7 is expressed). The peaks of these binding sites coincide with a CpG 
element that is methylated in several cell lines, including HepG2 (Myers and Absher, 
Costello et al.), suggesting that 7P10-E2 CpG methylation may influence regulatory 
protein binding. The histone mark H3K4me1 is enriched in this region in many ENCODE 
cell lines (Bernstein, The Encode Project, 2011), but not H3K27ac (Bernstein, The 
Encode Project, 2011). H3K27ac distinguishes active enhancers from poised or inactive 
enhancers that contain the H3K4me1 mark alone (Creyghton et al., 2010), indicating a 
poised enhancer at 7P10-E2 that is activated in cells expressing ADH7 including CP-A 
cells. 7P5 can bind CTCF in some cell lines (Myers et al., The Encode Project, 2011) as 
well as NF-κB and JunD transcription factors. Since the cells tested by ENCODE do not 
express ADH7 endogenously, the data may represent a poised enhancer in 7P10-E2. 
 
Our study suggests that variants affecting ADH7 gene regulation show combinatorial and 
cell-specific interactions. These findings highlight the complexity of interpreting the 
effects of individual SNPs, because they are dependent upon other SNPs that are in cis. 
Detailed analyses of haplotypes that are associated with alcohol-related traits will be 
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needed to identify which SNPs are functional and the consequences of different 
combinations of SNPs.  
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IV. CHAPTER II 
AN ENHANCER- BLOCKING ELEMENT REGULATES THE CELL-SPECIFIC 
EXPRESSION OF ALCOHOL DEHYDROGENASE 7 
 
1. INTRODUCTION 
ADH7 is unique among the ADHs in being expressed mainly in the esophagus and gastric 
mucosa but not in the liver, the primary site of expression of the other 6 ADHs (Engeland 
and Maret, 1993, Kedishvili et al., 1995). Regulatory elements extending up to -799 bp 
are active in HeLa, CV-1 monkey kidney, and H4IIE3 rat liver cells (Kotagiri and 
Edenberg, 1998).  The promoter and other regulatory elements in the ADH7 proximal 
region extending 12.5 kb upstream from the translation start site are also active in ADH7 
expressing CP-A, MEF and HepG2 cells, although there are cell-specific differences in 
the level of transcriptional activity (Chapter I) (Jairam and Edenberg, 2014). This 
suggests that other, more distant factors contribute to the cell-specific expression of 
ADH7.  
 
Enhancers can activate promoters over long distances (Bulger and Groudine, 2011, Chin-
Tong and Victor, 2011, Arnosti and Kulkarni, 2005). Several ADH enhancers have been 
identified that activate more than one ADH promoter including the potent FOXA-
dependent liver-specific enhancer located upstream of ADH4 (Pochareddy and Edenberg, 
2010) and the class I ADH HNF1-bound enhancer, located 10 kb downstream of ADH7 in 
the 60 kb intergenic region between ADH1C and ADH7 (Su et al., 2006). Yet, despite the 
presence and proximity of functional ADH enhancers, ADH7 is not expressed in the liver, 
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suggesting the possibility of an element that blocks the effect of these enhancers on 
ADH7. Chromatin insulators are known to exhibit this enhancer blocking activity, and all 
known vertebrate insulators bind the CCCTC binding factor CTCF. CTCF binding is, 
therefore, a candidate for enhancer blocking insulator function in the ADH locus. 
 
Bioinformatics analyses suggested that a region between the ADH class I enhancer and 
ADH7 is potentially an insulator element that can prevent the HNF1-bound enhancer 
from activating ADH7. We have analyzed the function of this region in cell systems that 
replicate the cell-specific pattern of endogenous ADH7 expression observed in vivo: CP-
A human esophageal cells and MEF (mouse embryonic fibroblast) cells that express 
ADH7 and HepG2 human hepatoma cells that do not. We have demonstrated that this 




A. Identification of iA1C, an enhancer blocker 
Since vertebrate insulator elements containing enhancer-blocking activity are typically 
associated with the CCCTC binding factor (CTCF), we searched the insulatordb (Bao et 
al., 2008) database for potential CTCF binding sites in the vicinity of ADH7 and found a 
965 bp sequence we called iA1C in the intergenic region between the enhancer and 
ADH7 (Figure 11) 
 
 





Figure 11: Location of the ADH class I enhancer (ENH) and iA1C. Top line is the 
part of chromosome 4 containing ADH7 and ADH1C; distances are in kb. Below, iA1C 
and ENH are expanded; distances (bp) are measured from the ADH7 translation start site 
(TSS, +1). iA1C is the sequence from 29277:30222.	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Figure 12: Map of the pXP2 plasmid construct used for insulator assays. The 
enhancer was cloned 1 kb upstream of the ADH7 promoter A7P. Test and control 




B. iA1C is a cell- and position-dependent insulator 
To test the potential enhancer blocking activity of the iA1C fragment, we cloned it 
upstream of the ADH7 promoter (A7P, with allele A at the functional SNP rs2851028 
(Jairam and Edenberg, 2014) on either or both sides of the enhancer ENH (Figure 12). 
Constructs were tested for effect on enhancer function in MEF and CP-A cells that 
express endogenous ADH7 (Chapter I) and in HepG2 cells that do not. ENH increased 
A7P promoter activity 2.2 fold in MEF cells, 2.4 fold in CP-A cells and 3.4 fold in 
HepG2 cells. iA1C significantly increased transcriptional activity of the enhancer-
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containing plasmids independent of its placement with respect to ENH in both CP-A and 
MEF cells though the effects were more pronounced in MEF cells (Figure 13).  
 
In HepG2 cells, iA1C caused a 60% reduction in enhancer activity when placed between 
ENH and A7P. When placed outside the enhancer, iA1C had a significant but much 
smaller effect on activity. Flanking ENH by iA1C on both sides had a dramatic and 
nearly complete block on ENH function, with the luciferase expression of the flanking 
construct only slightly higher (1.17 fold) than that of the promoter construct alone 
(Figure 13).  
 
When tested in combination with the known insulator element XL9 (that binds CTCF and 
regulates expression of the HLA-DRB1 and HLA-DQA1 genes (Majumder et al., 2008)), 
iA1C showed a similar cell- and position dependent behavior with no enhancer blocking 
function in CP-A and MEF cells (that express ADH7) (Figure 14). In HepG2 cells, iA1C 
placed between ENH and the promoter blocked enhancer activity by 50% when 
combined with XL9 on the other side of ENH. The construct with the reverse placement 
of iA1C and XL9 (XL9-ENH-iA1C-A7P) affected A7P activity by 2.4 fold with a 40% 
reduction in ENH activity, similar to the effect seen with XL9 flanking ENH on both 
sides (Figure 14).  Thus, iA1C had enhancer-blocking activity in HepG2 cells, and this 
activity was cell-specific and dependent on the placement of iA1C with respect to the 
enhancer.  
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Figure 13: iA1C is an insulator with cell-specific enhancer blocking activity. Effects 
of iA1C in MEF, CP-A and HepG2 cells tested using constructs with iA1C cloned on 
either or both sides of ENH as depicted were transiently transfected into the cells. 
Relative activities were the ratios of normalized luciferase activity of each construct to 
that of the promoter (A7P) construct shown at top in the same cell line. Error bars 
indicate standard errors of the mean. P-values reflect the differences between the 
normalized luciferase activity of each construct and the enhancer construct in 
corresponding cell type. * indicate p-values ≤ 0.006; ** indicate p-values ≤ 5 × 10-6; *** 
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Figure 14: iA1C function with XL9 insulator. Constructs with test iA1C and control 
XL9 fragments cloned on either or both sides of ENH as depicted were transiently 
transfected in MEF, CP-A and HepG2 cells. Luciferase activities were calculated by 
normalizing to the internal control β-galactosidase. Relative activities were determined 
by calculating the ratios of normalized luciferase activity of each construct to that of the 
promoter A7P construct. Error bars indicate standard errors of the mean. P-values reflect 
the differences between the normalized luciferase activity of each construct and the 
enhancer construct in corresponding cell type. * indicate p-values ≤ 5 × 10-4; ** indicate 
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C. Sub-fragmentation of iA1C to localize insulator function 
To localize the enhancer blocking activity, iA1C was fragmented into two overlapping 
shorter fragments of 630 bp and 395 bp, and tested for function. Transient transfections in 
HepG2 cells showed that enhancer activity was reduced by about 75% when flanked by 
either sub-fragment (Figure 15). The full- length iA1C was a more potent enhancer 
blocker than its sub-fragments, nearly completely eliminating enhancer effect. 
 
 
Figure 15: Effects of iA1C sub-fragments iA1C-1 and iA1C-2 in HepG2 cells relative 
to full length iA1C. The sub-fragments iA1C-1 and iA1C-2 contain the sequences from 
29277: 29917 and 29918:30222 with respect to ADH7 TSS. Relative activities in HepG2 
cells were determined as the ratio of normalized luciferase activity of each construct to 
that of the promoter vector. Standard errors of mean are shown. . P-values reflect the 
differences between the normalized luciferase activity of each construct and the enhancer 
construct. . * indicate p-values ≤ 1 × 10-6; ** indicate p-values ≤ 8 × 10-9; *** indicate p-
values ≤ 3 × 10-10 
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D. iA1C function with heterologous enhancer and promoter 
The pGL3 control vector containing the SV40 enhancer and SV40 promoter driving 
luciferase expression (Groskreutz et al., 1995) was used to study the function of iA1C 
with heterologous elements. Since the SV40 promoter and enhancer typically work well 
in nearly all cell types, they represent a great heterologous system, particularly to study 
cell-specificity. The SV40 enhancer increased SV40 promoter activity by 180 fold in CP-
A cells and approximately 10 fold in MEF and HepG2 cells, indicating that both the 
SV40 enhancer and promoter were functional in our cell systems (Figure 16). In both 
CP-A and MEF cells, the transcriptional activity of the construct with iA1C cloned 
immediately upstream of the SV40 promoter was similar to the transcriptional activity of 
pGL3 control vector, indicating no effect of iA1C on enhancer function. In HepG2 cells 
however, iA1C decreased SV40 enhancer activity by 40% (Figure 16). Thus, iA1C 
exhibits similar behavior independent of the enhancer and promoter elements, but 
dependent on the cellular context and status of endogenous ADH7 expression.  
  





Figure 16: iA1C functions as a cell specific insulator with heterologous enhancer 
and promoter. Transient transfections in A) MEF and HepG2 cells and B) CP-A cells, 
with pGL3 promoter vector (containing the SV40 promoter SVp), pGL3 control vector 
(containing SVp and the SV40 enhancer SVe), and iA1C cloned between SVp and SVe 
in the pGL3 control vector. Relative activities represent the ratio of normalized luciferase 
activity of each construct to that of the pGL3 promoter vector. P-values are the 
differences between the normalized luciferase activity of each construct and the SVe 
construct in the corresponding cell type. p-values ≤ 2.5 × 10-5 are indicated by  **; p-
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E. iA1C variants affect function 
Variants of regulatory elements can affect function. To study the effects of iA1C variants 
on its enhancer blocking activity, three constructs each containing a naturally occurring 
iA1C haplotype (Table 6) positioned between SV40 enhancer and promoter were tested 
by transient transfections in HepG2 cells. The enhancer increased SV40 promoter activity 
10-fold in HepG2 cells; the AC haplotype of iA1C used in earlier experiments reduced 
enhancer activity by 44% (Figure 17). We tested two additional haplotypes of iA1C 
(Table 6) in this system. The iA1C-GC haplotype had a similar effect while iA1C-GT 
had a slightly (but significantly) greater effect, reducing enhancer activity by 50% ( 






A C 30.8 NA07000 
G T 63.4 NA12248 
G C 5.8 NA12248 
 
Table 6: Variants of iA1C tested for effects on function. The alleles of the two SNPs 
making up the naturally occurring haplotypes of iA1C, their haplotype frequencies in 
Northern and Western European populations from Utah (CEU) and the DNA templates 
from Coriell Institute for Medical Research used for obtaining the sequences are listed. 
 




Figure 17: iA1C variants have a significant but slight effect on its enhancer blocking 
activity. Effects of different naturally occurring haplotypes of iA1C tested with the 
heterologous SV40 elements in HepG2 cells. iA1C-AC is the haplotype used in earlier 
assays. Standard errors of mean are shown. P-values represent the differences between 
the normalized luciferase activity of each construct and SVe construct containing SV40 
enhancer and are indicated by * for values≤ 5 × 10-5; ** for values≤ 1.75 × 10-6; *** for 
values= 1 × 10-9 
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F. iA1C binding to CTCF in vitro 
To test binding of the vertebrate insulator binding protein CTCF to iA1C in HepG2 cells 
in vitro, Electrophoretic Mobility Shift Assays (EMSA) were used. EMSA assays with 
iA1C-O, a 40 bp FAM-labeled oligonucleotide within iA1C (Figure 18) identified from 
the insulatordb database as a potential CTCF binding site, showed shifts in the binding 
when incubated with HepG2 nuclear extract (Figure 19; lane 2).  
 
Figure 18: A depiction of iA1C-O (Table 9), the 40 bp binding site predicted to bind 
CTCF. The location relative to full length iA1C and the enhancer ENH is shown. The 
map is drawn to scale with iA1C-O represented as a black box within iA1C. 
 
Competition assays with unlabeled oligonucleotides showed that loss of shift occurred 
with addition of increasing amount (5X and 10X) of specific competitor oligos (cold 
iA1C-O; lanes 8-9) or CTCF consensus oligos (CTCF-CON; lanes 10-11), but not with 
the non-specific competitor (NS; lane 3) indicating the binding was specific. Competition 
with oligonucleotides containing the iA1C sequence shuffled to disrupt the consensus 
CTCF binding site (iA1C-Osh; lanes 4-7) resulted in loss of both specific and nonspecific 
bands (Figure 19). However, addition of the Anti-CTCF antibody did not result in a 
supershift (Figure 20; lane 3) because the antibody directly bound the target oligo 
(Figure 20; lane 11). Similar direct interaction between CTCF antibody and positive 
control β-globin oligonucleotide that is known to bind CTCF was observed resulting in 
inconclusive evidence of whether or not CTCF binds to iA1C-O (Figure 20; lane 12).  
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Figure 19: Electrophoretic mobility shift assays (EMSA) to study protein binding to 
iA1C-O in vitro. Assays were done using labeled iA1C 40 bp oligonucleotide probe 
(iA1C-O) which was predicted to bind CTCF and HepG2 nuclear extract (HepG2 NE). 
Competition assays were done with nonspecific control (NS), iA1C-O shuffled to disrupt 
the consensus CTCF binding site (iA1C-Osh), cold iA1C-O and CTCF consensus oligo 
(CTCF-CON). An arrow points toward the specific band corresponding to iA1C binding 
to the HepG2 nuclear extract. Lanes are listed at the bottom. 
Labeled iA1C-O + + + + + + + + + + + 
HepG2 NE  + + + + + + + + + + 
NS   25X         
iA1C-Osh    5X 10X 25X 40X     
Cold iA1C-O        5X 10X   
CTCF-CON          5X 10X 
!!!!!!!!!!!!! !
! !!!!!!!!1! !!!!!!!2!!!!!!!3! !!!4! 5!!!!!!!!!6!!!!!!!7!!!!!!!8!!!!!!!9!!!!!10!!!!11!!
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Figure 20: Supershift assay with Anti-CTCF. To confirm binding, supershift assays 
were done using CTCF antibody and the iA1C-O. Controls included β-globin labeled 
probe and unlabeled cold probes (iA1C-O; iA1C-Osh=shuffled iA1C; CTCF-
CON=CTCF consensus oligo and β-globin). iA1C and β-globin labeled probes were 
incubated with Anti-CTCF alone (for control) or along with the HepG2 nuclear extracts. 
The components of each lane are shown. An arrow points toward the specific band 
corresponding to iA1C and β-globin binding to the HepG2 nuclear extract. 
Labeled'iA1C,O' +' +' +' +' +' +' ' ' ' ' +' '
Labeled'β,g' ' ' ' ' ' ' +' +' +' +' ' +'HepG2'NE' ' +' +' +' +' +' +' +' +' +' ' 'Cold'iA1C,O'(10X)' ' ' ' +' ' ' ' ' ' ' ' 'iA1C,Osh'(10X)' ' ' ' ' +' ' ' ' ' ' ' 'CTCF,CON'(10X)' ' ' ' ' ' +' ' ' ' +' ' 'β,globin''(10X)' ' ' ' ' ' ' ' ' +' ' ' 'Anti,CTCF' ' ' +' ' ' ' ' +' ' ' +' +'
''''''''''''''''''''' '''''''''!!!!!!!!!!!!!!!!!1!!!!!!!2!!!!!!!3! !!!4! 5!!!!!!!6!!!!!!7!!!!!!8!!!!!!9!!!!!10!!!11!!!!12!
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G. iA1C-O, the 40 bp sequence identified by insulatordb is not required for 
insulator activity 
To test if the 40 bp sequence iA1C-O contained insulator activity, transient transfections 
were done with the wild type and mutated oligonucleotides (used in the EMSA assays) 
cloned on either or both sides of the enhancer ENH into A7P promoter construct. The 
mutations were done so that the sequence no longer had the CTCF consensus-binding 
site. Transient transfections showed that neither the wild type nor the mutated oligo 
sequences had insulator activity, instead up-regulating ENH activity (Figure 21). Similar 
experiments with the full-length iA1C sequence mutated via site-directed mutagenesis 
(iA1C-SH) (Figure 22) to no longer contain the predicted CTCF consensus-binding site 
showed no difference in the enhancer blocking activity when compared to wild type full 
length iA1C.  
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Figure 21: iA1C-O does not contain enhancer blocking activity in HepG2 cells. 
Transient transfections in HepG2 cells with wild type iA1C oligonucleotide and mutated 
oligonucleotide sequences to test enhancer blocking function of the sequence predicted to 
bind CTCF in silico. Constructs with the wild type (O) or shuffled oligos (Osh) used in 
the EMSA assays cloned on either or both sides of ENH were tested, and none of them 
show enhancer blocking activity. Relative activities represent the ratio of normalized 
luciferase activity of each construct to that of the A7P promoter vector. T-tests for 
significance of the differences between the normalized luciferase activities of each 
construct and the enhancer construct ENH were carried out: * indicate p-values ≤ 0.08; 
** indicate p-values ≤ 9 × 10-4; *** indicate p-values ≤ 1 × 10-8  
ENH 
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Figure 22: Full length iA1C shuffled to disrupt the predicted CTCF binding site 
does not affect insulator function. Transient transfections in HepG2 cells with full 
length iA1C mutated to disrupt the consensus CTCF binding site cloned on either or both 
sides of the enhancer ENH. In this depiction, SH represents the full length sequence 
mutated to no longer contain the CTCF consensus site predicted in silico, instead carrying 
the shuffled 40 bp sequence used in EMSA assays. Relative activities represent the ratio 
of normalized luciferase activity of each construct to that of the A7P promoter vector. T-
tests were done for significant differences between the normalized luciferase activity of 
each construct and the enhancer construct ENH. * indicate p-values ≤ 8 × 10-4; ** 
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H. CTCF binds multiple sites within iA1C in vivo 
Since chromatin immunoprecipitation assays can detect in vivo binding and do not have 
some of the limitations of EMSA assays, ChIP assays were performed to identify any 
CTCF binding sites within iA1C. CTCF binding and enrichment of the target sequences 
in the immunoprecipitated samples are represented as yield, which are the ratio of signals 
obtained from ChIP to signals from a 4% input sample (the non-immunoprecipitated 
chromatin sample and serves as a control and as a measure of starting DNA material 
relative to which the immunoprecipitated chromatin can be measured). Of the eleven 
iA1C sub-fragments (Figure 24A) tested for CTCF binding by ChIP, the greatest binding 
was seen for iA1C-D, with the adjacent sub-fragment iA1C-C also showing high yield 
(Figure 24B). Another spike in yield is seen for iA1C-J, indicating multiple binding sites 
at or near the ends of iA1C in HepG2 cells. A random sequence from exon 3 of RPL30 
housekeeping gene does not bind CTCF in HepG2 cells, indicating the binding is 
specific. RPL30 binds the positive control histone H3 antibody, but not IgG confirming 
the validity of RPL30 as a control (Figure 23).  
 
In CP-A cells however, iA1C did not bind CTCF (Figure 24B). ChIP assays with 
positive control H3 and negative control IgG and the target sequence RPL30 indicate the 
ChIP assays worked as expected. Thus, there are significantly different binding patterns 
of CTCF to iA1C sub-sequences in HepG2 and CP-A cells.  




Figure 23: Semi-quantitative ChIP analysis of CTCF binding to controls using a 1% 
agarose gel run. Each of the four lanes shows PCR amplification of the control human 
exon 3 RPL30 sequence from different templates. Product from Lane 1) contains the 2% 
input sample as template, 2) positive control H3 and 3) negative control rabbit. Lane 4) 
shows the no DNA control for PCR. The molecular weights of bands up to 1000 bp are 
listed in bp on left side of the panel. On the right side, an arrow points toward the band 
corresponding to RPL30 amplicon of size 161 bp. 
  
Figure'S1'















         
Figure 24: CTCF binds multiple sites within iA1C in vivo, but only in HepG2 cells. 
A) iA1C subsequences used in Chromatin immunoprecipitation (ChIP) assays. iA1C- A 
to J are 100-150 bp sequences encompassing the full length of iA1C. K is immediately 
downstream of iA1C and serves as a control, along with human RPL30. The targets C, D 
and J with the greatest enrichment for CTCF in HepG2 cells are depicted on sequence, 
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EMSA assays is shown as an oval within iA1C. B) CTCF binding to iA1C subsequences 
in HepG2 and CP-A cells, determined by ChIP. A random sequence in the housekeeping 
gene RPL30 serves as a control. Yields represent the ratio of signals obtained from ChIP 
to signals from a 4% input sample, which is the non-immunoprecipitated chromatin 
sample and serves as a control and as a measure of starting DNA material relative to 
which the immunoprecipitated chromatin can be measured. Means and standard errors 
from two or three biological replicates and at least 12 technical replicates in total are 
shown. Statistical significance between yields (2^ (Input Ct-IP Ct)) of each target and 
RPL30 control were calculated by t-tests. * indicate p-values ≤ 0.015; ** indicate p-
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I. CTCF knockdown is insufficient to induce ADH7 in liver cells 
Since iA1C is an insulator that cell specifically blocks activation of the ADH7 promoter 
and binds CTCF with the same specificity, it is likely that CTCF plays a role in iA1C 
enhancer blocking activity and regulation of ADH7 expression. To study the effect of 
CTCF knockdown on ADH7 expression, HepG2 cells were infected with adenovirus 
encoding CTCF shRNA (shCTCF). Cells infected simultaneously with control shRNA 
(shctrl) served as reference. Samples from untreated HepG2 and CP-A cells served as 
controls. qPCR assays with cDNA amplified from RNA samples (extracted from the 
shCTCF or shctrl infected cells) showed that CTCF was highly expressed in cells treated 
with either shRNA (Table 7), with a 2-fold reduction in CTCF expression in the shCTCF 
samples relative to shctrl samples. CTCF was still highly expressed even with the 50% 
decrease achieved by this CTCF shRNA (Table 7) and was insufficient to induce ADH7 
expression in HepG2 cells to a level that was detectable by qPCR assay. The control 
genes H19 and PUMA, which are moderately expressed in HepG2 cells and are affected 
by changes in CTCF levels according to published literature (Gomes and Espinosa, 
2010), showed 1-1.5 fold induction with CTCF knockdown.   
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cDNA 
sample Target Ct Mean Stdev 
2^ (shCTCF 
Ct-shctrl Ct) 
shctrl CTCF 25.54 0.48 
2.26 shCTCF CTCF 26.72 0.19 
 
shctrl ADH7 39.36 
 - shCTCF ADH7 - 
  
shctrl H19 32.90 0.20 
1.48 shCTCF H19 33.47 0.31 
 
shctrl PUMA 28.71 0.20 
1.05 shCTCF PUMA 28.78 0.07 
Table 7: Changes in the levels of gene transcripts in HepG2 cells on CTCF 
knockdown assayed by qPCR. The knockdown achieved a 2 fold reduction in 
expression between the CTCF shRNA and control shRNA samples. ADH7 mRNA in 
control samples is virtually undetectable, whereas there is a very modest induction in H19 
and PUMA mRNA levels with CTCF knockdown. shctrl and shCTCF represent cDNA 
from the control shRNA and CTCF shRNA infected samples respectively. Differential 
gene expression is measured by the value of 2^ (shCTCF Ct-shctrl Ct) and mean Ct 
values for each target with both cDNA samples is shown. Biological replicates=6. 
Technical replicates=24 for each target mRNA. 
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3. DISCUSSION 
In this chapter, we identified an intergenic element, designated iA1C, that is located 
between the ADH7 gene and the class I ADH specific enhancer ENH (Su et al., 2006) and 
blocks ENH activity in the ADH7 promoter in HepG2 cells. The enhancer blocking 
activity was dependent on the placement of iA1C with respect to the enhancer and 
promoter, acting only when iA1C was placed between the two elements. This insulator 
function was specific to cell-type, with no enhancer blocking activity in ADH7-
expressing CP-A cells or MEF cells. CTCF bound multiple sites within iA1C in HepG2 
cells but no binding was seen in CP-A cells, suggesting CTCF binding may be required 
for iA1C insulator function. Since CTCF is highly expressed in both HepG2 and CP-A 
cells, the cell specific binding is not a function of CTCF availability.  
 
iA1C showed cell-specificity even on a widely expressed heterologous promoter-
enhancer pair from SV40. Thus, the cell-specificity resides within iA1C itself. 
Interestingly, the effects of the various regulatory elements were very similar in some 
aspects while different in others in the two cell types that express ADH7, CP-A cells and 
MEF cells. However, the general trend remained similar with the upstream elements 
showing promoter specific effects: greater increase or smaller decrease when combined 
with A7P-A and the opposite with A7P-G. Similarly, iA1C had no enhancer blocking 
activity with either the ADH HNF1-bound enhancer (ENH) or the much more potent 
SV40 enhancer in both ADH7 expressing cell types. iA1C insulator function and cell-
specificity with the potent SV40 enhancer suggests that it protects the ADH7 promoter 
from not just the proximal class I ADH enhancer, but from other distal enhancers as well.  
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Chromatin insulators have emerged as important factors in the spatial and topological 
organization of higher order chromatin structures and functional transcriptional domains 
(Phillips-Cremins and Corces, 2013, Van Bortle and Corces, 2012). Insulators can 
employ any one or a combination of mechanisms depending on cell type and target 
enhancers and promoters (Valenzuela and Kamakaka, 2006, Wallace and Felsenfeld, 
2007, Bushey et al., 2008, Zhu et al., 2007). All vertebrate insulators identified so far 
bind CTCF. CTCF can interact with itself forming homodimers, with other regulatory 
proteins (Merkenschlager and Odom, 2013, Weth and Renkawitz, 2011), and also with 
the nuclear lamina causing DNA looping and formation of cis- and trans- chromatin 
domains and influencing cross talk between gene promoters and regulatory elements 
(Phillips and Corces, 2009, Williams and Flavell, 2008). Cell specific interactions 
between CTCF bound sequences are known to regulate the cell specific expression of 
linked genes such as the b-globin cluster (Junier et al., 2012, Ren et al., 2012). 
 
Since our results show that unbound iA1C correlates with a lack of enhancer blocking 
activity, it is probable that CTCF binding is a necessary event for iA1C function as an 
insulator on this element. However, the test for an induction of ADH7 expression in 
HepG2 cells by knockdown of CTCF mediated by adenoviral shRNA proved ineffectual. 
Because of the complete absence of ADH7 in HepG2 cells, a high level of induction 
would be needed to register in a qPCR assay. CTCF is also very highly expressed in 
HepG2 cells so that even with a 50% knockdown (or a ΔΔCt value of 2), CTCF mRNA 
was present at high levels indicating insufficient CTCF mRNA degradation. However, 
while mRNA degradation is a primary mechanism of shRNA mediated gene silencing, 
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other mechanisms include translation repression. To test for gene silencing by translation 
repression, CTCF protein levels in the CTCF shRNA and control shRNA treated cells 
should be compared to correctly ascertain knockdown efficiency. Irrespective of the level 
of CTCF knockdown, because of the complete absence of ADH7 in untreated HepG2 
cells, a high level of induction would be needed to register in a qPCR assay. Such 
induction was not achieved in this experiment. Therefore, evidence of the fate of ADH7 
expression on 2-fold CTCF mRNA knockdown is inconclusive. 
 
 CTCF levels in untreated HepG2 cells (Ct=23.5) is 10 fold lower than GAPDH levels 
(Ct=18.7); relatively, CTCF levels in CP-A cells (Ct=25.5) were 4 fold lower than those 
in HepG2 cells starting with similar RNA and cDNA amounts and handled similarly. The 
high levels of CTCF in both HepG2 and CP-A cells indicate mechanisms other than 
CTCF availability influence binding to iA1C. Some of these potential mechanisms that 
can play a role in cell specific CTCF binding include the differential methylation status of 
the CTCF binding sites within iA1C, differently compacted chromatin structures (open vs 
closed chromatin) and competition/ differential occupation of regulatory protein binding 
sites (including CTCF binding sites) in the two cell types. 
 
iA1C is DNaseI hypersensitive in nearly all cell lines tested by ENCODE (Bernstein et 
al.), which does not include CP-A or MEF cells, and is also predicted to bind the typical 
CTCF binding partner, Rad21 (Myers et al., The Encode Project, 2011) which is a 
component of the cohesin complex. ENH is located less than 2 kb downstream of iA1C, 
and the intervening sequence is a DNaseI hypersensitive region bound by several 
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different transcription factors including AP-1 and NF-κB family (Myers et al., The 
Encode Project, 2011). The MafK and MafF transcription factors belonging to the AP-1 
family can bind this region as well as 7P10-E2, the enhancer located 12 kb upstream of 
ADH7 gene. The Maf (v-maf avian Musculoaponeurotic fibrosarcoma oncogene 
homolog) proteins can dimerize by physically interacting with each other (Motohashi et 
al., 2004). This 2 kb region encompassing iA1C and ENH may be a potential locus 
control region, regulating the tissue-specific expression of multiple ADH genes. 
 
The ENCODE project has identified potential CTCF binding sites (Myers et al., 
Bernstein et al., The Encode Project, 2011) in the intergenic regions between ADH5-
ADH4, ADH1C-ADH7 and ADH7-C4orf17 including a site corresponding to our element 
iA1C. ADH7, which is not expressed in the liver at all unlike the adjacent ADHs, may be 
part of a chromatin domain formed by the interactions between iA1C and the CTCF 
binding site between ADH7 and C4orf17. The necessity of such a structure is emphasized 
by fact that the genes further upstream of C4orf17 are either housekeeping genes like 
TRMT10A (tRNA Methyl Transferase Homolog 10A) or differently expressed like MTTP 
(Microsomal Triglyceride Transfer Protein). Indeed, the ENCODE ChIP-PET 
Interactions track identifies potential interactions between iA1C and the CTCF site 
between ADH7-C4orf17 supporting our model. Our results show that iA1C protects the 
promoter from the non-homologous SV40 enhancer indicating that it may be involved in 
blocking other ADH7 non-relevant regulatory elements like the much stronger ADH4 
enhancer 4E3. 
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We have shown that iA1C insulates the ADH7 gene from the class I ADH enhancer ENH, 
and also the heterologous SV40 enhancer, in liver derived cells. We demonstrate that the 
function of iA1C is cell-specific, as is the binding of CTCF to iA1C. Thus we conclude 
that the insulator iA1C helps determine the tissue specificity of ADH7 expression. There 
is a small but significant difference in function due to genetic variation at rs1442489. 
Chapter I demonstrated cell specificity and significant effects of genetic variations in 
several more proximal elements, including an enhancer 7P10 and the ADH7 promoter 
itself (Jairam and Edenberg, 2014). Thus, a combination of factors is important for the 
overall and precise regulation of ADH7 transcription. 
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V. CONCLUSIONS and FUTURE DIRECTIONS 
The main objective of my dissertation was the identification of elements regulating 
ADH7 transcription and variants having significant effects on regulation. Since most of 
the reported disease associations belong to the 5’ LD block of ADH7, the first research 
objective focused on the 12.5 kb conserved region upstream of ADH7 and its variants. 
This was based on the hypothesis that the causal variants for at least some of the reported 
associations affect ADH7 regulation and expression levels, since the only known non-
synonymous cSNP was associated with cancer but not with alcoholism or alcohol 
metabolism. An alteration of gene expression can influence enzyme levels and the 
contribution of ADH7 to substrate metabolism, and ultimately risk for alcoholism and 
cancer.  
 
An analysis of the LD pattern between the SNPs in the upstream region and disease 
associated SNPs showed that each major disease phenotype was associated with a distinct 
LD block comprising SNPs with little overlap between the 3 blocks. Upstream variants 
were identified through their effects on regulatory function and ADH7 promoter activity. 
The promoter SNP, that is in LD with SNPs associated with alcoholism and alcohol 
related cancer and causes a 2-fold difference in activity, is particularly important. The 
causal variant for a particular disease phenotype is not always the SNP identified by an 
association study; instead, any SNP having significant association with a particular 
disease phenotype actually represents the association of at least one SNP that is in LD 
with the original SNP. In cases such as this where the originally identified SNP has no 
apparent effect on protein levels or gene expression, it is likely the causal variant is a 
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SNP that is in LD with the original SNP and affects either transcript or protein levels. 
Thus, the promoter SNP is a potential causal variant for protection against alcoholism and 
risk for UADT cancers. Another important finding is the identification of the enhancer 
7P10 and its variants that significantly affect function, and are in LD with the only 
reported non-synonymous coding SNP as well as SNPs associated with alcohol 
metabolism. The promoter and upstream variants interact in a cell-specific and allele-
specific manner complicating the interpretation of effects of individual SNPs. These 
regulatory elements are functional in HepG2 cells and do not explain the tissue-specific 
expression of ADH7. 
 
My second objective was to better understand ADH7 tissue specific expression, 
particularly the lack of ADH7 expression in the liver in the presence of proximal 
functional enhancers. This was accomplished by the identification of iA1C, a cell-
specific and position-dependent insulator that blocked the class I ADH HNF1 bound 
enhancer (ENH) from activating the ADH7 promoter in hepatoma cells; it behaved 
similarly with the more potent heterologous SV40 enhancer. iA1C also bound CTCF cell-
specifically, validating the original hypothesis and experimental approach to the project 
which was based on the in silico identification of iA1C as a potential CTCF binding site 
on the premise that a chromatin insulator was involved. Based on its location (between 
ADH7 and the rest of the ADH cluster) and properties, iA1C likely protects ADH7 from 
being expressed in the liver by blocking ectopic ADH enhancers (mainly liver-specific). 
It could also work the other way as a barrier element to block ADH7 enhancers (7P10-
E2) from activating other ADHs in ectopic tissues (Figure 25).  
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Figure 25: Regulatory elements in the ADH region. ADH regulatory elements with the 
strongest effects and that are relevant to this thesis mapped in a diagram drawn to scale. 
The ADHs are listed on sequence in the direction of transcription orientation. Known 
enhancers are listed as line arrows, iA1C as plain circle and the ADH7 promoter as solid 
circle. The insulator iA1C blocks the ADH7 promoter A7P-A/G from activation in the 
liver by other ADH enhancers, ENH and likely 4E3 (Pochareddy and Edenberg, 2010). It 
could also block the ADH7 enhancer from activating the other ADH promoters in ectopic 
tissues like the esophagus. 
 
Together, this dissertation identified elements that regulate ADH7 tissue specific 
expression and variants affecting this regulation in physiologically relevant cell systems. 
While the upstream regulatory elements have smaller but still significant effects in the 
cell-specific expression of ADH7, iA1C has a more important role. On the other hand, the 
influence of the upstream variants on regulation is more potent compared to the effect of 
the smaller, but still significant effect of the iA1C variants. This is consistent with the 
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fact that most reported disease associations of ADH7 lie within the 5’ LD block. It is 
likely that the smaller genetic influence on iA1C function is related to the need to 
preserve the integrity of ADH7 (and possibly other ADHs) tissue-specific expression. In 
conclusion, genetic factors determine the level of ADH7 transcriptional activity while 
iA1C helps determine the fate of transcription, thus providing an overall picture of ADH7 
regulation. Human and mouse cell lines replicating ADH7 tissue specific expression were 
used as models in this study and while they cannot duplicate the full complexity of in 
vivo systems, they worked well in the context of this dissertation.  
 
Future work could continue and build on this knowledge using a combination of 
bioinformatics and experimental approaches. A more detailed analysis of the regulatory 
element haplotypes associated with diseases could be done to identify additional 
functional SNPs, particularly rare alleles. My work focused mainly on common 
haplotypes occurring naturally in the Western and Northern European populations 
(CEU). Future work on rarer haplotypes needs to be undertaken since it has been shown 
that the protective ADH1B*2 allele that is common mainly in the East Asians has a 
significant protective effect in other populations as well. Opposite haplotypes of 
important regulatory regions can be tested first to gain an initial understanding of the 
potential effect of the variants in the haplotype. For example, 7P5-ATAC and 7P5-GCGT 
had a significant difference in function in HepG2 cells suggesting that a more detailed 
study of the other haplotypes is needed to help decipher the likely causal variant. The 
differences in activities of promoter and regulatory element haplotypes could be due to 
differential binding of regulatory proteins. In silico prediction tools like PROMO and 
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Transfac can be used to help prioritize potential candidates. The list can be further 
narrowed by looking for transcription factors important for expression of other genes in 
specific epithelial tissues like the esophagus, which can then be tested for binding target 
sequences by in vivo and in vitro binding assays. Haplotype specific binding can be 
studied by searching for regulatory proteins that only bind one haplotype of the target 
sequence, losing their consensus binding sites on alteration of the DNA sequence. The 
enhancer 7P10-E2 can be characterized further. The genome wide ENCODE consortium 
and 1000 Genome data available publicly can also be used to identify other elements with 
regulatory potential by looking for characteristics like histone modifications, DNaseI 
hypersensitivity and transcription factor binding.  
 
The iA1C insulator could also be characterized further. The potential barrier function of 
iA1C could be studied by stably transfecting a reporter gene sequence flanked by iA1C 
into HepG2 cells, followed by testing for protection against position effects by assaying 
reporter activity. Epigenetic studies like DNA methylation and histone modifications can 
be done to decipher iA1C properties; comparison studies in HepG2 and CP-A cells could 
explain the cell specific CTCF binding. CTCF bound insulators can form domains by 
interacting with each other and with the nuclear architecture. iA1C binding to the nuclear 
architecture can be studied by the nuclear matrix attachment assay or DamID technique 
which is based on the targeted adenine methylation (in the sequence GATC) of sequences 
interacting in vivo with the HepG2 nuclear lamina integrated lamin-DNA adenine 
methyltransferase fusion protein (Dam).  
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The ENCODE consortium and insulatordb database predict other potential CTCF binding 
sites in the ADH cluster. Chromosome conformation capture (3C) assays can be used to 
study interactions between iA1C and the other potential CTCF bound sites. The potential 
formation of domains by the interactions between the CTCF bound sites and the nuclear 
lamina could play a vital role in the tissue specific expression of all the ADHs. The 
approximately 1 kb region between iA1C and the class I enhancer ENH is DNaseI 
hypersensitive in many cell lines (Bernstein et al., The Encode Project, 2011) and is 
bound by many different transcription factors (Myers et al., The Encode Project, 2011) 
indicating high regulatory potential. However, since none of the cell lines tested by 
ENCODE express ADH7, they are not the best systems to study ADH expression. 
Therefore, while the transcription factors identified by ENCODE do not affirmatively 
predict binding or function in relevant cell systems, they can be used as a guide for 
further studies in this region. Knockdown assays resulting in greater (nearly complete) 
knockdown of CTCF can be attempted to test ADH7 induction. Similar knockdown 
experiments to specifically test the reversal of enhancer blocking by iA1C can be done by 
co-transfection of iA1C plasmids and CTCF shRNA adenovirus. CTCF heterozygous 
mice are viable (Heath et al., 2008, Moore et al., 2012) and can be used to study the 
profile of ADH expression in the liver and other tissues of the heterozygotes.  
 
Genome editing technology can be used to manipulate the different regulatory elements 
in vivo for more detailed studies of function. For example, iA1C sequence can be directly 
deleted in HepG2 cells and effect on ADH expression tested. Genome editing technology 
uses artificially engineered nucleases to insert, delete or replace DNA by creating specific 
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double strand breaks in the genome, which are then repaired by the cell’s endogenous 
mechanisms of homology directed repair and nonhomologous end-joining. The recently 
discovered Crispr technology, which was first identified as a natural defense system used 
by bacteria against invading viruses, can be used to target any region of the genome with 
very high accuracy with the help of the DNA endonuclease Cas9 (Crispr associated 
nuclease-9) (Richter et al., 2013). Since the only requirement for Crispr mediated genome 
editing is the Cas9 nuclease and a small guide RNA that can base pair with the target 
sequence and guide the endonuclease to generate double strand breaks in the sequence, it 
is a simple, straightforward tool for site-specific engineering that is easy to implement 
and can be used to generate a wealth of physiologically relevant information in vivo. 
These studies will help further the understanding of regulation of the alcohol 
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APPENDIX A 
 
Table 8: Primers used for generating test and control fragments for CHAPTER I. 
Primer names, the complete sequence including restriction sites and the test fragments 
amplified from the primer pairs are listed. 
  
Description Primer name Sequence


















7P10 HE3781 GACGGTACCTGAGTTGCTGGTCTGTCCC 
7P10 HE3782 CCGCTCGAGGCTTGAATGATACCTTGTGCTC 
7P10-E1 HE4620 CCCAAGCTTGAGTTGCTGGTCTGTCCCACA 
7P10-E1 HE4621 CCGCTCGAGAGTTACAAATGTCACAAGTGTGAGTG 
7P10-E2 HE4622 CCCAAGCTTCTCATTGAATGAATAAAAGATTTATTGCC 
7P10-E2 HE4623 CCGCTCGAGGACAACACTGATACCTAAATGTAAACTAC
7P10-E3 HE4624 CCCAAGCTTCTGGCTGGTAGAACTTTCATTTACTAAG
7P10-E3 HE4625 CCGCTCGAGCTTTGATTTTGGACTTCTGGTGttc 
7P10-E2flip HE4800 CCGCTCGAGCTCATTGAATGAATAAAAGATTTATTGCC
7P10-E2flip HE4801 CCCAAGCTTGACAACACTGATACCTAAATGTAAACTAC
7P10-E2far HE4802 CGCAATGGGCCCCTCATTGAATGAATAAAAGATTTATTGCC 
7P10-E2far HE4803 CCCATTTAAATGACAACACTGATACCTAAATGTAAACTAC
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APPENDIX B 
 
Table 9: Primers and oligonucleotide probes used in CHAPTER II. Primer/oligo 
names, the complete sequence including restriction sites and the test fragments amplified 




iA1C HE3552 ATGCGATCGCATCTTGGAGCACCCATCACTTGAGCG 
iA1C HE3553 ATTGCCGGCCCTTCAGGTTTTCCACCAGACAAATC 
iA1C HE3546 CGGACGCGTATCTTGGAGCACCCATCACTTGAGCG 
iA1C HE3547 ACTTCGCGACCTTCAGGTTTTCCACCAGACAAATC 
XL9 HE3542 ATGCGATCGCTTCGGTGTCCAAGTGTCAAAAAGG 
XL9 HE3543 ATTGCCGGCTGTGGTATGAAAGTGAGGGTAGGTG 
XL9 HE3538 GGGACGCGTTTCGGTGTCCAAGTGTCAAAAAGG 












iA1C-A HE4833 TTGGAGCACCCATCACTTG 
iA1C-A HE4834 CAAATGAGGACGCAAAAGC 
iA1C-B HE4835 CCTGAGTCCCCAAAGTTCAC 
iA1C-B HE4836 GGAATGGAAAACCAAACACTGTATG 
iA1C-C HE4837 GTTTGGTTTTCCATTCCTGAG 
iA1C-C HE4838 TGCTGCCACCTTCCTGC 
iA1C-D HE4839 TGAGGGCAGGAAGGTGG 
iA1C-D HE4840 GGAAAAGAGAAGCAATCAAGG 
iA1C-E HE4841 CCAGCAGAACTGAGAAAATAAGG 




iA1C-G HE4846 ATGGGATCATTCTGTGGGATT 
iA1C-H HE4847 TCCCACAGAATGATCCCAT
iA1C-H HE4848 CCACTGAATGCTTAGGGTTG
iA1C-I HE4849 TCAACCCTAAGCATTCAGTGG 
iA1C-I HE4850 TTCTCAGCCTAATCAGTAAGACG 
iA1C-J HE4851 CGTCTTACTGATTAGGCTGAGAA 
iA1C-J HE4852 CCTTCAGGTTTTCCACCAGA 
iA1C-K HE4853 GGAAAACCTGAAGGTAGGACC
iA1C-K HE4854 TTCAACATCCCTTATTGGAGTG
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